THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY, CHENNAI



PHASE II MBBS 2024 – 2025 BATCH ACADEMIC SCHEDULE

ACADEMIC CALENDAR

			Academic	calenda	r for ad	missio	n bate	h 2024-	2025			
	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
Adm year										1 14 Oct	2	3
Phase 1 exam	4	5	6	7	8	9	10	11	Phase 1 exam, result	13 Phase 2 starts	14	15
Phase 2 exam	16	17	18	19	20	21	22	23	Phase 2 exam, result	25 Phase 3 part 1 starts	26	27
Phase 3 part I exam	28	29	30	31	32	33	34	35	36 Phase 3 Part 1 exam, result	37 Phase 3 part 2 starts	38	39
	40	41	42	43	44	45	46	47	48	49	50	51
Phase 3 part II exam	52	53	54 Proposed NEXT step1	1 CRMI	2	3	4	5	6	7	8	9
Internship	10	11	Proposed NEXT step2									

Legends:

CRMI-Compulsory rotating medical internship

Time allotted: 12 months (approx. 52 weeks)

Time available: Approx. 39 weeks (excluding 13 weeks)

(Prelim/University Exam & Results - 9 weeks + Vacation - 2 weeks + Public Holidays -2 weeks)

39 wks x 39 hrs = 1521 hrs available hours for Teaching-Learning

Distribution of Subject Wise Teaching Hours for Phase-2 MBBS

Subjects	Large group teaching	SGT/ Practicals/ Tutorials/ Seminars	Clinical Postings*	SDL	Total
Pathology	80	170	0.74	10	260
Pharmacology	80	170	349	10	260
Microbiology	75	143	0.78	10	228
Community Med (including FAP)	25	0	24	10	59
Forensic Medicine and Toxicology	12	25	-	08	45
Clinical Subjects	60		540	570	600
AETCOM	220	29	-	8	37
Sports, Yoga extra- curricular activities	\$ 3 8	<u>a</u>	253	32	32
Final total	332	537	564	88	1521

SGT: Small group teaching SDL: Self-directed learning

Pl. note: *Clinical postings shall be for 3 hours per day, Monday to Friday.

There will be 15 hours per week for all clinical postings.

	AETCOM PI	nase 2
Subject	Paper	Module number
Microbiology	Paper 1	2.1
	Paper 2	2.8
Pharmacology	Paper 1	2.2, 2.3
	Paper 2	2.5
Pathology	Paper 1	2.4
	Paper 2	2.7

CLINICAL POSTING SCHEDULES

SUBJECT	WEEKS
General Medicine	8
General Surgery	6
Obstetrics & Gynaecology	6
Paediatrics	4
Community Medicine	4
Oto-Rhino-Laryngology	4
Ophthalmology	4
Total	36

The timings of Clinical Postings shall be utilized for conduction of preliminary Examination (Model Examination) for Phase II Subjects after completion of 36 weeks of Clinical Postings.

NOTE: INTERNAL ASSESSMENT

The internal assessment marks for each subject will be out of 100 for theory and out of 100 for practical/clinical (except in General Medicine, General Surgery and Obstetrics & Gynaecology, in which theory and practical assessment will be of 200 marks each).

For subjects that teach in more than one phase, cumulative IA to be used as eligibility criteria. The final cumulative marks are to be used for eligibility. The details are:

I. General medicine: The IA of 200 marks in medicine shall be divided across phases as

Phase II - 50 marks,
Phase III part 1 - 50 marks
Phase III part 2 - 100 marks.

Phase III part 2 - 100 marks is divided as

Medicine - 75 marks Psychiatry - 13 marks Dermatology- 12 marks.

The final cumulative IA for Medicine is out of 200 marks for theory and practical each.

II. General surgery: The IA in surgery shall be divided across phases as:

Phase III part 1 - 25 marks
Phase III part 1 - 25 marks
Phase III part 2 - 150 marks

Phase III part 2 - 150 marks shall be divided as

General surgery -75 marks
Orthopedics -50 marks
Anesthesia -13 marks
Radiodiagnosis -12 marks

The final cumulative IA for surgery is out of 200 marks for theory and practical each.

- III. IA of Forensic Medicine and Toxicology is divided as 25 marks in phase II and 75 marks in Phase III part 1. The final cumulative IA is out of 100 for theory and practical each.
- IV. IA in Community Medicine is divided as 25 marks in phase I, 25 marks in phase II, and 50 marks in Phase III- part 1. The final cumulative IA for Community Medicine is out of 100 marks for theory and practical each.
- V. IA in ophthalmology and ENT is divided as 25 marks in phase II and 75 marks in Phase III part 1. The final cumulative IA is out of 100 for theory and practical each for each subject.

	01-10-2025	02-10-2025	03-10-2025	04-10-2025	05-10-2025
TIME	Wednesday	Thursday	Friday	Saturday	Sunday
08.00 – 11.00 A.M.		HOLIDAY	Orientation to Phase II MBBS Program	Orientation to Phase II MBBS Program	
11.30 – 12.30 P.M.			Orientation to Phase II MBBS Program	Orientation to Phase II MBBS Program	
12.30 - 01.30 P.M.			LUNCH	LUNCH	
01.30 – 02.30 P.M.			Orientation to Phase II MBBS Program	Orientation to Phase II MBBS Program	
02.30 – 03.30 P.M.			Orientation to Phase II MBBS Program	Orientation to Phase II MBBS Program	
03.30 – 04.30 P.M.			Orientation to Phase II MBBS Program	Orientation to Phase II MBBS Program	

	06-10-2025	07-10-2025	08-10-2025	09-10-2025	10-10-2025	11-10-2025	12-10-2025
TIME	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL THEORY		
11.30 – 12.30 P.M.	SU 1.1 DESCRIBE BASIC CONCEPTS OF HOMEOSTASIS, ENUMERATE THE METABOLIC CHANGES IN INJURY AND THEIR MEDIATORS.	PA1.3 Describe proliferation and cell cycle and concept of regenerative medicine along with role of stem cells.	PH 1.4 Identify the common drug formulations and drug delivery systems, demonstrate their use and describe their advantages and disadvantages. (LGT)	MI 1.1 Role of microbes in health and disease (LGT)	SU 1.2 DESCRIBE THE FACTORS THAT AFFECT THE METABOLIC RESPONSE TO INJURY.	HOLIDAY	
12.30 - 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.	FM1.1 Define Forensic medicine, Clinical Forensic Medicine, Forensic Pathology, State Medicine, Legal Medicine and Medical Jurisprudence	MI 1.1 Introduction, History & Scope of microbiology (LGT)	PA2.1 Describe the causes, mechanisms, types and effects of cell injury and their clinical significance PA2.2 Describe the etiology of cell injury. Distinguish between reversible, irreversible injury: mechanisms; morphology of cell injury	PH1.3 Describe nomenclature of drugs i.e., generic, branded drugs and scheduled drugs, explaining the utility of the nomenclature, cost effectiveness and use.(SGT)	PHI.2 Describe evidence based medicine and rational use of drugs & discuss why these are relevant to therapeutics. (LGT)		
			PRACTICALS				
02.30 – 03.30 P.M.	PAL-1 Describe the role of a pathologist in diagnosis and management of disease PAL-2 Enumerate common definitions and terms used in Pathology and Describe the history and evolution of Pathology				SU 1.2 DESCRIBE THE FACTORS THAT AFFECT THE METABOLIC RESPONSE TO INJURY. LUNCH PHI.2 Describe evidence based medicine and rational use of drug		
03.30 – 04.30 P.M.	PHI.1 Describe the principles of pharmacology, pharmacotherapeutics and define various terms in pharmacology, (LGT)	· ·	al) Describe the principles of pharmacology, pharmacotherapeutics and define various logy: MI 1.6 Demonstration of all sample collection and transport & MI 1.6 lab req SGT case based discussion Pathology - Introduction to Practicals SGT				

	13-10-2025	14-10-2025	15-10-2025	16-10-2025	17-10-2025	18-10-2025	9-10-202
TIME	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
11.30 – 12.30 F.M.	OG 2.1 Development and anatomy of female reproductive tract and its relationship with other pelvic organs and applied anatomy	PA2.3 Describe morphological changes in intracellular accumulation of fats, proteins, carbohydrates, pigments PA2.5 Describe types and pathology of calcifications and gangrene PA2.6 Describe cellular adaptations: atrophy, hypertrophy, hyperplasia, dysplasia and carcinoma in situ	PH1.6 Describe salient features of absorption, distribution, metabolism and excretion of drugs with emphasis on various routes of drug administration (LGT)	MI 1.2.3 Physiology / characteristics of bacteria (LGT)	OG 3.1 Physiology of ovulation, menstruation, fertilization, implantation and gametogenesis	8.00 – 02.00 FAP,CM	
12.30 - 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.	FM1.2 Describe history of Forensic MedicineFM1.3 Describe legal competencies including Bharatiya Nagarika Suraksha Sanhta (BNSS), Bharatiya Nyay Sanhta (BNS) Bharatiya Sakshya Sahhiya (BAA), Protection of Children from Sexual Offences Act (POCSO) Civil and Criminal Cases, Inquest (Police Inquest and Magistrate's Inquest), Cognizable and Non-cognizable offences	MI 1.2.2 Morphology of bacteria (LGT)	PA2.7 Describe the mechanisms of cellular aging	PH1.6 Describe salient features of absorption, distribution, metabolism and excretion of drugs with emphasis on various routes of drug administration (LGT)	PH1.7 Describe various principles of mechanism of action of drugs (Receptor)(LGT)		
			PRACTICALS				
02.30 - 03.30 P.M.	P.A.2.4 Describe and explain Cell death-types, mechanisms, apoptosis (basic as contrasted with necrosis), autolysis				MI 1.2.4 General Taxonomy, Classification of bacteria, virus, fungi, parasites (LGT)	CM3.1 Describe the health hazards of air, water, noise, radiation and pollution	
03.30 - 04.30 P.M.	PH1.6 Describe salient features of absorption (including drug transport mechanism), distribution, metabolism and excretion of drugs with emphasis on various routes of drug administration (LGT)	PH 1.4 Identify the common drug formulations and	of cell injuries with their manifestations and conseque GROSS – FATTY LIVER, INFARCT SPLEEN HEP – FATTY LIVER OSPE CHART - NECROSIS and description of the control of the c	ribe their advantages and disadvantages. (P/SGT)	PAS.1 Define and describe edema, correlations its types, pathogenesis and clinical correlations	CM3.1 Describe the health hazards of air, water, noise, radiation and pollution	

	20-10-2025	21-10-2025	22-10-2025	23-10-2025	24-10-2025	25-10-2025	26-10-2025
TIME	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
08.00 – 11.00 A.M.		CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	Saturday	
11.30 – 12.30 P.M.		PA5.2 Define and describe hyperemia, congestion, hemorrhage	PH1.7 Describe various principles of mechanism of action of drugs (Dose Response Relationship)(SGT)	MI 1.2.6 Overview of Common viral infections/ diseases (LGT)	PATHOGENESIS OF FEVER GM4.1-Describe and discuss the febrile response and the influence of host immune status, risk factors and comorbidities on the febrile response GM4.4-Describe and discuss the pathophysiology and manifestations of inflammatory causes of fever		
12.30 - 01.30 P.M.		LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.		MI 1.2.5 Overview of Common bacterial infections/ diseases (LGT)	PAS.4 Define and describe normal haemostasis and the etiopathogenesis and consequences of thrombosis	PH1.7 Describe various principles of mechanism of action of drugs (Factors modifying drug action), PH1.13 Identify and describe the management of drug interactions(LGT)	PH 1.9 Select rational drug combinations based on the pharmacokinetics/pharmacodynamic (PK/PD) parameters with emphasis on synergism, antagonism, "therapeutic efficacy", risk benefit ratio (LGT)	gism, CM3.2 Describe concepts of safe and wholesome water, sanitary sources of water, water purification processes, water quality standards, concepts of water conservation and rainwater harvesting CM3.2 Describe concepts of safe and wholesome water, sanitary sources of water water purification processes, water quality standards,	
		P	RACTICALS MICRO/PATH/PHARM				
02.30 - 03.30 P.M.					MI 1.2.7 Overview of Common fungal infections/ diseases (LGT)	of water, water purification processes, water quality standards,	
03.30 – 04.30 P.M.		PHI.4 Identify the common drug formulations and drug delivery syst Microbiology: MI 1.6 Urine sample collection from a catherterised ps Pathology: PA5.6 Identify and describe the gross and microscopic fer HPE – CVC Lung, CVC Liver, CVC Spleen Gross – CVC Spleen	CENCEAL POSTNOS CENCEA	of water, water purification processes, water quality standards,			

	27-10-2025	28-10-2025	29-10-2025	30-10-2025	31-10-2025	01-11-2025	02-11-2025
TIME	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	8.00 – 02.00 FAP,CM	
11.30 – 12.30 P.M.	SU 1.3 DESCRIBE BASIC CONCEPTS OF PERIOPERATIVE CARE.	SDL/Revision – Cell injury , Hemodynamic disorders	PH 1.11 Define Adverse Drug Reactions (ADRs) & their types. Identify the ADRs in the given case scenario and assess causality.(LGT)	MI 1.3.1, 11.1.1 Bacterial genetics & its significance in infectious diseases (LGT)	SU 2.1 DESCRIBE PATHOPHYSIOLOGY OF SHOCK, TYPES OF SHOCK & PRINCIPLES OF RESUSCITATION INCLUDING FLUID REPLACEMENT AND MONITORING		
12.30 - 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.	FM1.4 Describe Courts in India and their powers: Supreme Court, High Court, Sessions court, Magistrate's Court, Labour Court, Family Court, Executive Magistrate Court and Juvenile Justice Board	MI 1.2.8 Overview of Common parasitic infections/ diseases (LGT)	PA6.1 Define and classify neoplasia. Describe the characteristics of neoplasia including gross, microscopy, Biological, behavior and spread. Differentiate between benign from malignant neoplasms	PH 1.12 Define Pharmacovigilance its principles and demonstrate ADR reporting (SGT)	PHI0.10 Identify when therapeutic drug monitoring is considered for a particular patient, determine timing of sampling and calculate revised dose.(SGT/Tutorial)		
			PRACTICALS MICRO/PATH/PHARM			Saturday 8.00 – 02.00 FAP,CM 8.00 – 02.00 FAP,CM CM3.3 Describe the actiology and basis of water borne diseases /jaundice/hepatitis/ diarrheal diseases CM3.4 Describe the concept of solid waste, human excreta and sewage	
02.30 – 03.30 P.M.	PA5.3 Define and describe shock, its pathogenesis and its stage				MI 1.3.2 Basic principles of molecular biology & discuss the molecular techniques applied to disease diagnosis (LGT)		
03.30 – 04.30 P.M.	PH 1.10 Describe changes in pharmacology of drugs in geriatric, pediatric and special situations such as Pregnancy, lactation, hepatic and renal disorders and adjust the drug treatment accordingly. (SGT/PBL)	intranasal sprays and inhalers (P/SGT) Microbiology: MI 1.10, 7.4 Perform Gram stain to id	n, their advantages and disadvantages and demonstrate administ entify the different causative agents of infectious diseases from d microscopic features of Benign and malignant neoplasm in a pman, Lipoma, Secondary deposits node	the clinical specimen- Demonstration (DOAP)	PA6.2 Describe the molecular basis of cancer	human excreta and sewage	

	03-11-2025	04-11-2025	05-11-2025	06-11-2025	07-11-2025	08-11-2025	09-11-2025
TIME	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
11.30 – 12.30 F.M.	OG 4.1 Basic embryology and factors influencing fetal growth and development, anatomy and physiology of placenta, teratogenes	PA6.2 Describe the molecular basis of cancer	PH10.12 Describe overview of drug development including phases of clinical trials and Good Clinical Practice & reflect on the role of research in developing new drugs (LGT)	MI 1.4.2 Laboratory methods used to detect causative agents- Culture media & culture methods (LGT)	h-Gume) resur	Saturday	
12.30 - 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
	FM1.5 Describe Court competencies including issue of Summons, conduct money, types of witnesses, recording of evidence oath, affirmation, examination in chief, cross examination, re-examination and court questions, recording of evidence & conduct of doctor in witness box	MI 1.4.1 Laboratory methods used to detect causative agents- Direct microscopy & workflow in a laboratory (LGT)	PA6.2 Describe the role of genetic and epigenetic alterations with special emphasis on common cancers like breast/colon	PH10.8 Describe Essential medicines, Fixed dose combination, Over the counter drugs and explain steps to choose essential medicines.(SGT)	PH1.1 - 1.13 Tutorials		
			PRACTICALS MICRO/PATH/PHARM				
02.30 – 03.30 P.M.	PA6.2 Describe the molecular basis of cancer				MI 1.4.3 Laboratory methods used to detect causative agents- Identification methods (conventional) (LGT)		
03.30 – 04.30 P.M.	PHIO.11 Identify and apply drug Regulations principles, acts and legal aspects related of drug discovery and clinical use (LGT)	sprays and inhalers (P/SGT) Microbiology: MI 1.10, 7.4 Perform Gram stain to i	on, their advantages and disadvantages and demonstrate administrati- dentify the different causative agents of infectious diseases from the rs (2), Paraneoplastic syndromes(2), Charts related to Molecular basi	clinical specimen- Gram positive cocci (DOAP)	PA6.3 Define and classify the carcinogens and describe the process of different types of carcinogenesis		

	10-11-2025	11-11-2025	12-11-2025	13-11-2025	14-11-2025	15-11-2025	16-11-2025
TIME	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
11.30 – 12.30 P.M.	FEVER AND HYPERTHERMIA GM4.2 - Describe and discuss the patho-physiology and differences between fever and hyperthermia. GM4.3 - Enumerate various common causes of fever and hyperthermia in various regions in India.	SDL/Revision - Neoplasia	PH2.7 Define pain and enumerate drugs used for pain. Explain salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of analgesics including NSAIDs (except opioids) (Prostaglandins and Leukotrienes) (LGT)	MI 1.4.5, 11.1.2 Laboratory diagnosis of bacterial infections Antimicrobial susceptibility testing (SGT)	-ACUTE FEBRILE ILLNESS: GM4.6 Discuss the approach to the patient with Acute Febrile Illness.	salient drug ALDS CM3.6 Describe the role of vectors in the causation of diseases. Also diseases. Also diseases Control Program CM3.7 Identify and describe the identifying features and life	
12.30 - 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.	FMI.6 Describe Offenses in Court including Perjury; Court strictures visavis Medical Officer	MI 1.4.4 Laboratory methods used to detect causative agents- Identification methods (automated) (LGT)	PA7.1 Describe the techniques of cytology, staining & diagnostic role of cytology and its application in clinical care	PH2.7 Define pain and enumerate drugs used for pain. Explain salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of analgesics including NSAIDs (except opioids) (NSAIDS -I) (LGT)	PH2.7 Define pain and enumerate drugs used for pain. Explain salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of analgesics including NSAIDs (except opioids) (NSAIDS – II) (LGT/SDL/Flipped Classroom)		
			PRACTICALS MICRO/PATH/PHARM				
02.30 – 03.30 P.M.	PA6.4 Describe the effects of tumor on the host including para neoplastic syndrome PA6.5 Describe laboratory diagnosis of cancer including molecular profiles of tumors, tumors markers and future of cancer diagnostics PA6.6 Describe immunology and the immune response to cancer with its clinical significance – Immunotherapy				CLINICAL POSTINGS ACUTE FEBRILE ILLNESS: GM4.6 Discuss the approach to the patient with Acute Febrile Illness. 8.00 – 02.00 FAP,CM LUNCH PH2.7 Define pain and enumerate drugs used for pain. Explain salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of analgesies including NSAIDs (except opioids) (NSAIDS – II) (LGT/SDL/Flipped Classroom) MI 1.5 Sample collection and transport of specimens with lab request writing (LGT) writing (LGT) CM3.6 Describe the role of vectors in the causation of diseases. Also discuss National Vector Borne disease Control Program CM3.7 Identify and describe the identifying features and life vectors of Public Health importance and their control importance and their co		
03.30 – 04.30 P.M.		Pharmacology Exercise(P/SGT)	identify the different causative agents of infectious of	deminentic drugs used for plantesis for a control of the plantesis of the of the plante	identifying features and life cycles of vectors of Public Health importance and their control		

	17-11-2025	18-11-2025	19-11-2025	20-11-2025	21-11-2025	22-11-2025	23-11-2025
TIME	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
11.30 – 12.30 P.M.	SU 2.2 DESCRIBE THE CLINICAL FEATURES OF SHOCK AND ITS APPROPRIATE TREATMENT		PHARM IA (General Pharmacology)	MI 1.8 Discuss & demonstrate effective communication skills with patient, relative and clinicians and pre/posttest counseling (Role play)	SU 3.1 DESCRIBE THE INDICATIONS AND APPROPRIATE USE OF BLOOD AND BLOOD PRODUCTS AND COMPLICATIONS OF BLOOD TRANSFUSION.	8.00 - 02.00 FAP CM	
12.30 - 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
	FM1.7 Describe Dying Declaration & Dying Deposition	MI 1.7 Discuss attitude & behaviour that portrays respect & demonstrate respect for patient samples sent to the laboratory for performance of laboratory tests in the detection of microbial agents (SGT - Role play)	PA11.1 Describe the diagnostic modalities of common cytogenetic abnormalities and mutations in childhood	PH2.8 Devise management plan for a case of	PH2.8 Devise management plan for a case of gout, arthritis and migraine using appropriate drugs (Drugs for Gout) (LGT/CBL)	S.00 – 02.00 FAP,CM graine CM3.8 Describe the mode of action, application cycle of commonly used insecticides and rodenticides	
		PRACTICALS M	ICRO/PATH/PHARM				
02.30 - 03.30 P.M.	PA11.1 Describe the pathogenesis and features of common cytogenetic abnormalities and mutations in childhood				MI 1.9 Demonstrate confidentiality pertaining to patient identity in laboratory results (SGT / Role play)	commonly used	
03.30 – 04.30 P.M.	PH2.8 Devise management plan for a case of gout, arthritis and migraine using appropriate drugs (Serotonin agonists and its antagonists & Drugs for Migraine)(LGT/PBL)	PH1.6 Describe salient features of absorption, distribution, metabolism an Climical Pharmacology Exercise(P/SGT) Microbiology. MI 1.10, 7.4 Perform Gram stain to identify the different can egative bacilli & Gram positive cocci (DOAP) Pathology: HPE – Wilms tumor Pathology OSPE charts – Diseases of Infancy and childhood (4)		-	PA11.2 Describe the pathogenesis and pathology of tumors in infancy and childhood	CM3.5 Describe the standards of housing and the effect of housing on health	

	24-11-2025	25-11-2025	26-11-2025	27-11-2025	28-11-2025	29-11-2025 30-1	11-2025
TIME	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday St	Sunday
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
11.30 – 12.30 P.M.	OG 7.1 Maternal changes during pregnancy - CVS, Renal, GIT, Respiratory , Hematology, Genital tract	PA11.3 Describe the pathogenesis of common storage disorders in infancy and childhood	PH2.2 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of cholinergic and anticholinergic drugs and demonstrate OPC poisoning management (Introduction to ANS and Direct cholinergies) (LGT)	MI 1.12.1 Classification, methods of sterilisation, quality control and its application in laboratory, clinical and surgical practice (LGT)	OG 8.1 Objective of AN care, Screening for high risk factors	8.00 – 02.00 FAP,CM	
12.30 - 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.	FM1.8 Describe the latest decisions/notifications/resolutions/ circulars/standing orders related to medico-legal practice issued by Courts/Government authorities etc.	MI 1.11 Describe the epidemiological basis of infectious diseases and their application. (LGT)	PA10.1 Define and describe the pathogenesis and pathology of malaria PA10.2 Define and describe the pathogenesis and pathology of cysticercosis	PH2.2 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of cholinergic and anticholinergic drugs and demonstrate OPC poisoning management (Cholinergic agonists –Indirect/Anticholinesterases) (LGT/CBL)	PH2.2 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of cholinergic and anticholinergic drugs and demonstrate OPC poisoning management (Anti-Cholinergics) (LGT)		
			PRACTICALS MICRO/PATH/PHARM				
02.30 - 03.30 P.M.	PA11.2 Describe the pathogenesis and pathology of tumor like conditions in infancy and childhood				MI 1.12.2 Classification, methods of disinfection, quality control and its application in laboratory, clinical and surgical practice (LGT)	CM9.1 Define and describe the principles of Demography, Demographic cycle, Vital statistics	
03.30 – 04.30 P.M.	PH2.6-2.8 Tutorials	calculation(P/SGT)// PH GP Viva Microbiology: MI 1.6, 3.3 Blood collection for Pathology: Hematology slide – Malarial paras	berculous lymphadenitis in a gross and microscopic specimen	SDL PA10.3 Define and describe the pathogenesis and pathology of leprosy	CM9.2 Define, calculate and interpret demographic indices including birth rate, death rate, fertility rates		

	01-12-2025	02-12-2025	03-12-2025	04-12-2025	05-12-2025	06-12-2025	07-12-2025
TIME	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
11.30 – 12.30 P.M.	HEAT RELATED ILLNESS: GM4.8: Describe and discuss the pathophysiology, clinical features and management of heat related illness (heat cramps, heat exhaustion and heat stroke)	PAI0.4 Define and describe the pathogenesis and pathology of common bacterial, viral, protozoal and helminthic diseases	PH2.1 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of adrenergic and antiadrenergic drugs (Alpha blockers) (LGT)	MI 2.1 Immunological mechanism in health and disease- Innate & acquired immunity (LGT)	ANEMIA, ETIOLOGY & CLASSIFICATION: GM9.1: Define, describe and classify anemia based on red blood cell Size and reticulocyte count GM9.2: Describe and discuss the morphological characteristics, Aetiology and prevalence of each of the causes of anemia	8.00 – 02.00 FAP,CM	
12.30 - 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.	- maintenance of incurrence register in a content register documents of issuance of wound certificate - documents of issuance of drunkenness certificate.	MI 1.13, 10.3 Choose the most appropriate method of sterilization and disinfection to be used in specific situations in the laboratory, in clinical and surgical practice, Seggregation of Biomedical Waste (LGT)	SDL 12.1Enumerate and describe the pathogenesis of disorders caused by air pollution, tobacco, alcohol and noise	PH2.1 Describe types, salient pharmacokineties, pharmacodynamics, therapeutiu uses, adverse drug reactions of adrenergic and antiadrenergic drugs (Beta blockers) (LGT)	PH9.7 Describe drugs used in glaucoma and other ocular disorders including topical (ocular) drug delivery systems (LGT)		
		PRA	CTICALS MICRO/PATH/PHARM	-			
02.30 – 03.30 P.M.	PA10.5 Define and describe the pathogenesis and pathology and laboratory findings in COVID				MI 2.2.1 Structure and function of the immune system (LGT)	CM9.5 Describe the methods of population control	
03.30 – 04.30 P.M.		PH 10.7 Describe Pharmacogenomics and Pharmacoecor given medication(s)(P/SCT) Microbiology: MI 2.5, 9.3 Choose the most suitable micr laboratory tests for the diagnosis of the infectious diseas Pathology: OSPE CHARTS (5) – PEM, Obesity, Vitami	robiological investigation in a given clinical e- Widal, RPR, Latex Agglutination - SGT of	situation and Interpret the results of the	IAI – Cell Injury, Hemodynamic disorders, Neoplasia, Genetics	CM9.6 Describe the National Population Policy CM9.7 Enumerate the sources of vital statistics including census, SRS, NFHS, NSSO etc	

	08-12-2025	09-12-2025	10-12-2025	11-12-2025	12-12-2025	13-12-2025	14-12-2025
TIME	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
11.30 – 12.30 P.M.	SU 4.1 ELICIT DOCUMENT AND PRESENT HISTORY IN A CASE OF BURNS AND PERFORM PHYSICAL EXAMINATION. DESCRIBE PATHOPHYSIOLOGY OF BURNS.	PA12.3 Describe the pathogenesis of obesity and its consequences with special emphasis on metabolic syndrome	PH2.1,2.2 Tutorials	MI 2.2.3 Complement system (LGT)	SU 4.2 DESCRIBE CLINICAL FEATURES, DIAGNOSE TYPE AND EXTENT OF BURNS AND PLAN APPROPRIATE TREATMENT.		
12.30 - 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.	FM1.9 Describe the importance of documentation in medical practice in regard to medico legal examinations, Medical Certificates and medico legal reports especially maintenance of patient case records, discharge summary, prescribed registers to be maintained in Health Centres. — maintenance of medico-legal register like accident register. -documents of issuance of wound certificate -documents of issuance of wound certificate. -documents of issuance of sickness and fitness certificate. -documents for issuance of sold no certificate, adocuments of Medical Certification of Cause of Death - Form Number4 and -documents for estimation of age by physical, dental and radiological examination and issuance of certificate	MI 2.2.2 Antigen, antibody (SGT)	SDL/ Revision – Genetics, Disorders of Infancy and childhood, Infections, Environmental and nutritional disorders	PH2.4 Explain salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of skeletal muscle relaxants (LGT)	PH2.5 Explain types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of local anaesthetics (LGT)		
			PRACTICALS MICRO/PATH/PHAI	RM			
02.30 - 03.30 P.M.	PA12.2 Describe the pathogenesis of disorders caused by protein calorie malnutrition, vitamins and starvation				MI 2.3.1 Host immune response in microbial infections- Humoral immune response (LGT)		
03.30 – 04.30 P.M.	PH2.2 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of cholinergic and anticholinergic drugs and demonstrate OPC poisoning management(Ganglionic stimulants and Blockers) SGT		n & effects of common prototype drugs on human itain to identify the different causative agents of inf	body using computer assisted learning (P/SGT) ectious diseases from the clinical specimen- certifiable skill	PA3.1 Define and describe the general features of acute and chronic inflammation including stimuli, vascular and cellular events		

	15-12-2025	16-12-2025	17-12-2025	18-12-2025	19-12-2025	20-12-2025	21-12-2025
TIME	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
	OG 8.6 & 8.7 Nutrition and Indication and types of vaccination during pregnancy	P.A.3.3 Define and describe chronic inflammation including causes, types nonspecific and granulomatous and enumerate examples of each	PH IA (ANS, Autocoids)	iniections) (SQL)	incomplete, inevitable, missed and septic abortion	8.00 – 02.00 FAP,CM	
12.30 - 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.	FM2.1 Select appropriate cause of death in a particular scenario by referring ICD 11 code	MI 2.3.2 Host immune response in microbial infections- Cellular immune response (LGT)	P.A.I. Define and describe the process of repair and regeneration including wound healing and its types	PH4.5 Explain types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of Diuretics, antidiuretics vasopressin and analogues (LGT)	PH4.5 Explain types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of Diuretics, antidiuretics vasopressin and analogues (SGT/seminar)		
		response					
02.30 – 03.30 P.M.	PA3.2 Enumerate and describe the mediators of acute inflammation				General Microbiology - MI 1.1 to 1.13 (Theory Assessment)	CM13.1 Define and describe the concept of Disaster management CM13.2 Describe disaster management cycle	
03.30 – 04.30 P.M.		Viva Microbiology: MI 2.5, 9.3 Choose the most suital	effects of common prototype drugs on human body using complete microbiological investigation in a given clinical situation anatography, CLIA, ELISA, Immunofluorescence- SGT case but at issue	and Interpret the results of the laboratory tests for the	PA8.1 Describe the principles and mechanisms involved in immunity PA8.2 Describe the mechanism of hypersensitivity reaction I and II	CM13.4 Describe the details of the National Disaster management Authority CM13.3 Describe man made disasters in the world and in India	

	22-12-2025	23-12-2025	24-12-2025	25-12-2025	26-12-2025	27-12-2025	28-12-2025
TIME	22-12-2025 Monday	23-12-2025 Tuesday	24-12-2025 Wednesday	25-12-2025 Thursday	26-12-2025 Friday	27-12-2025 Saturday	28-12-2025 Sunday
08.00 – 11.00 A.M.							
11.30 – 12.30 P.M.							
12.30 - 01.30 P.M.							
01.30 – 02.30 P.M.							
02.30 – 03.30 P.M.							
03.30 – 04.30 P.M.							

	29-12-2025	30-12-2025	31-12-2025	01-01-2026	02-01-2026	03-01-2026	04-01-2026
TIME	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
08.00 – 11.00 A.M.					CLINICAL POSTINGS		
11.30 – 12.30 P.M.					INVESTIGATIONS & MANAGEMENT OF ANEMIA: GM9.7: Describe and discuss the meaning and utility of components of the hemogram, various tests for iron deficiency, red cell indices, reticulocyte count, inostudies, peripheral smear, B12 and folate levels GM9.8: Describe the indications and interpret the results of a bone marrowaspirations and biopsy GM9.9: Describe, develop a diagnostic plan to determine the aetiology of anemia	8.00 – 02.00 FAP,CM	
12.30 – 01.30 P.M.					LUNCH	0.00 02.00 111 je.ni	
01.30 – 02.30 P.M.					PH4.6 Explain salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs modulating renin angiotensin aldosterone system. (SGT)		
02.30 – 03.30 P.M.					MI 2.5.1 Principles and applications of laboratory tests used in diagnostic microbiology based on the host's immune response: Antigen- Antibody reactions I (SGT)	CM14.1 Define and classify hospital waste CM14.2 Describe various methods of treatment of hospital waste CM14.3 Describe laws related to hospital waste management	
03.30 – 04.30 P.M.					PAS 2 Describe the mechanism of hypersensitivity reaction III and IV	CM14.1 Define and classify hospital waste CM14.2 Describe various methods of treatment of hospital waste CM14.3 Describe laws related to hospital waste management	

	05-01-2026	06-01-2026	07-01-2026	08-01-2026	09-01-2026	10-01-2026	11-01-2026
TIME	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
11.30 – 12.30 P.M.	SU 4.3 DISCUSS THE MEDICOLEGAL ASPECTS IN BURN INJURIES.	PA8.4 Define autoimmunity. Enumerate autoimmune disorder and describe the pathogenesis of common autoimmune diseases	PH4.7 Explain types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for the management of hypertension. Devise plan for pharmacologic management of hypertension with Diabetes, Pregnancy induced hypertension and hypertensive emergency and urgency (SGT/CBL)	MI 2.6 Immunoprophylaxis & Herd immunity. Discuss about Vaccine trials. (SGT)	SU 5.1 DESCRIBE NORMAL WOUND HEALING AND FACTORS AFFECTING HEALING.		
12.30 - 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.	FM2.2 Write a correct Medical Certificate of Cause of Death (MCCD) certificate as per ICD 11 document	MI 2.5.2 Principles and applications of laboratory tests used in diagnostic microbiology based on the hosts immune response: Antigen-Antibody reactions II (LGT)	PA8.5 Define and describe the pathogenesis of systemic Lupus Erythematosus	PH4.8 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for the management of ischemic heart disease (stable, unstable angina and myocardial infarction), peripheral vascular disease and devise management plan for a patient of acute myocardial Infarction (LGT)	PH4.8 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for the management of ischemic heart disease (stable, unstable angina and myacardiai infarction), peripheral vascular disease and devise management plan for a patient of acute myocardial Infarction (SGT/CBL)		
			PRACTICALS MICRO/PATH/PHARM				
02.30 - 03.30 P.M.	PA8.3 Describe the HLA system and the immune principles involved in transplant and mechanism of transplant rejection				MI 2.7.1 Immunological mechanism & laboratory methods- Hypersensitivity (LGT)		
03.30 – 04.30 P.M.	PH4.7 Explain types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for the management of hypertension. Devise plan for pharmacologic management of hypertension with Diabetes, Pregnancy induced hypertension and hypertensive emergency and urgency (LGT/CBL)	PH1.12 Define Pharmacovigilance its principles and Microbiology: MI 2.5, 9.3 Immunoserology exercises Pathology: OSPE CHARTS(3) – Autoimmunity Case based learning (2) - Autoimmunity			SDL PA8.6 Define and describe the pathogenesis and pathology of HIV and AIDS		

	12-01-2026	13-01-2026	14-01-2026	15-01-2026	16-01-2026	17-01-2026	18-01-2026
TIME	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
11.30 – 12.30 P.M.	OG 9.3 Etiology, clinical features, differential diagnosis of ectopic pregnancy, principles of medical and surgical management	SDL/Revision – Immunology, HIV	PHARM	MICRO	CLINICAL THEORY		
12.30 - 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.	FM2.3 Define, describe and discuss death and its types including somatic/clinical/cellular, molecular and brain-death, Cortical Death and Brainstem Death	MI 2.7.2 Immunological mechanism & laboratory methods- Autoimmunity (LGT)	РАТН	THARM	PHARM		
		P	PRACTICALS MICRO/PATH/PHARM				
02.30 – 03.30 P.M.	PA9.1 Describe the pathogenesis and pathology of amyloidosis				MiCRO		
03.30 – 04.30 P.M.	PH4.10 Explain salient pharmacokineties, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for cardiac arrhythmias. Devise a plan to manage a patient with supraventricular, ventricular arrhythmias, cardiac arrest and fibrillations (LGT/SDL)	PH1.12 Define Pharmacovigilance its principles and demonstrate A Microbiology. MI 10.3 Handwashing technique & Segreggation of E Pathology - SDL PA9.1Amyloidosis		ратн			

	19-01-2026	20-01-2026	21-01-2026	22-01-2026	23-01-2026	24-01-2026	25-01-2026
TIME	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
11.30 – 12.30 P.M.	HYPERTENSION GM8.1 - Describe and discuss the epidemiology, aetiology and the prevalence of primary and secondary hypertension GM8.2 - Describe and discuss the pathophysiology of hypertension GM8.3 - Define and classify hypertension GM8.4 - Describe and discuss the differences between primary and secondary hypertension GM8.6: Describe and discuss the clinical manifestations of the various aetiologies of secondary causes of hypertension	PA26.1 Distinguish arteriosclerosis from atherosclerosis. Describe the pathogenesis and pathology of various causes and types of atherosclerosis	PH4.9 Explain salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for the management of heart failure. Devise management plan for heart failure patients and Describe the strategies to prevent long term complications of heart failure. (SGT/CBL/SDL)	MI 2.8.1 Immunological mechanisms in Transplantation and its application in disease manangement & Immunohaematology (LGT)	HYPERTENSIVE EMERGENCY AND MANAGEMENT OF HYPERTENSIVE EMERGENCIES GM8.5: Define, describe and discuss and recognise hypertensive urgency and emergency GM8.7: Describe, discuss and identify urget organ damage due to hypertension GM8.13 - Develop an appropriate treatment plan for essential hypertension GM8.14 - Recognise, prioritise and manage hypertensive emergencies GM8.19 - Determine the need for specialist consultation	8.00 – 02.00 FAP,CM	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.	FM2.4 Describe salient features of the Organ Transplantation and The Human Organ Transplant (Amendment) Act 2011 and discuss ethical issues regarding organ donation	MI 2.7.3 Immunological mechanism & laboratory methods- lmmunodeficiency disorders (SGT)	PA26.2 Describe the etiology, dynamics, pathology types and complications of aneurysms including aortic aneurysms	PH 4.5-4.10 CVS Tutorials PH 4.5-4.10 CVS Tutorials therapeutic uses, adverse drug reactions of drugs used for different anaemias and thrombocytopenia. (LGT/SDL)			
			PRACTICALS MICRO/PATH/PHARM				
02.30 – 03.30 P.M.	IA2- Diseases of Infancy and childhood, Infections, Environment and nutritional disorders, Inflammation, Immunology, HIV and Amyloidosis				MI 2.8.2 Immunological mechanisms in tumor immunity and its application in disease manangement (SDL)	CM19.1 Define and describe the concept of Essential Medicine List (EML) CM19.2 Describe roles of essential medicine in primary health care CM19.3 Describe counterfeit medicine and its prevention	
03.30 – 04.30 P.M.	PH4.9 Explain salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for the management of heart failure. Devise management plan for heart failure patients and Describe the strategies to prevent long term complications of heart failure. (LGT)	Microbiology: MI 10.3 Handwashing Pathology: HPE – Atherosclerosis . T	nagement of drug interactions (Clinical Problem technique & Segreggation of Biomedical waste Thrombus MIC HEART DISEASE, RHEUMATIC FEVER MIC	(DOAP)	PA26.3 Describe the etiology, types, stages pathophysiology, pathology and complications of heart failure PA26.4 Describe the etiology, pathophysiology, pathology, gross and, complications of Congenital heart disease	CM19.1 Define and describe the concept of Essential Medicine List (EML) CM19.2 Describe roles of essential medicine in primary health care CM19.3 Describe counterfeit medicine and its prevention	

	26-01-2026	27-01-2026	28-01-2026	29-01-2026	30-01-2026	31-01-2026	01-02-2026
TIME	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
08.00 – 11.00 A.M.		CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
11.30 – 12.30 P.M.		PA26.5 Describe the etiology, pathophysiology, pathology, gross and microscopic features, criteria and complications of rheumatic fever	PH4.2 Explain types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs acting on coagulation system (Coagulants/anticoagulants) and devise a plan to monitor therapy and management of adverse effects. (LGT)	MI 3.2, 3.3 Describe the classification etio-pathogenesis, clinical features & lab diagnosis of Infective endocarditis (IE)(LGT)	SU 5.3 DIFFERENTIATE THE VARIOUS TYPES OF WOUNDS,PLAN AND OBSERVE MANAGEMENT OF WOUNDS.	8.00 – 02.00 FAP.CM	
12.30 - 01.30 P.M.		LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.		MI 3.1 Discuss the etiopathogenesis, clinical features, complications/ sequelae and laboratory diagnosis of rheumatic fever (LGT)	PA26.6 Describe the epidemiology, risk factors, etiology, pathophysiology, pathophysiology, presentations, gross and microscopic features, diagnostic tests and complications of ischemic heart disease	PH4.2 Explain types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs acting on coagulation system (Congulants/anticoagulants) and devise a plan to monitor therapy and management of adverse effects. (SGTI/CBL)	PH4.3 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of Fibrinolytics and Antifibrinolytic agents. (LCIT)		
			PRACTICALS MICRO/PATH/PHARM				
02.30 – 03.30 P.M.					MI 3.3 Sepsis (LGT)	PCT[Portion cover test] (CM3.1-3.4,CM 3.6-3.7, CM9.1-9.7, CM 13.1-13.3, CM14.1-14.3,CM19.1- 19.3)	
03.30 – 04.30 P.M.		PH 10.4 Describe parts of a correct, rational and legible prescription and wr competencies) (P/SGTI/CBL) Microbiology: MI 1.6 Urine sample collection from a catherterised patient & Pathology: Viva, Mentor-Mentee Meeting		of conditions to be used are given with other relevant	PA26.6 Interpret abnormalities in cardiac function testing in acute coronary syndromes	PCT[Portion cover test] (CM3.1-3.4,CM 3.6-3.7, CM9.1-9.7, CM 13.1-13.3, CM14.1-14.3,CM19.1- 19.3)	

	02-02-2026	03-02-2026	04-02-2026	05-02-2026	06-02-2026	07-02-2026	08-02-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	PCT PH (GP, ANS, PNS, Autocoids, CVS)	
11.30 – 12.30 P.M.		PA26.7 Describe the etiology, pathophysiology, pathology, gross and microscopic features, diagnosis and complications of infective endocarditis	PH4.11 Explain salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for the management of dyslipidaemias and enumerate drugs leading to dyslipidaemias (LGT/CBL)	MI 3.5 Define & describe types of Pyrexia of unknown origin (PUO). Discuss the etiopathogenesis and diagnostic modalities available (SDL)	PH 8.1 Discuss general principles of chemotherapy with emphasis on antimicrobial resistance. PH 8.2 Discuss rational use of antimicrobials and describe antibiotic stewardship program of your institute (LGT)	MI 3.6 Enteric fever: Classification, evolution of the clinical course, pathogenesis, complications, laboratory diagnosis and prevention (LGT)	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	
01.30 – 02.30 P.M.	PH4.4 Explain types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of Antiplatelets agents. (PGT/CBL)	MI 3.4 Diagnose a clinically suspected case of rheumatic fever/IE based on the findings of various microscopic, serological and culture investigations. (SGT)	PA26.9 Classify and describe the etiology, types, pathophysiology, pathology, gross and microscopic features, diagnosis and complications of cardiomyopathies	PH 4.1-4.4, 4.11 Tutorials	PA26.8 Describe the etiology, pathophysiology, pathology, gross and microscopic features, diagnosis and complications of pericarditis and pericardial effusion PA26.10 Describe the etiology, pathophysiology, pathology features and complications of tumors of cardiovascular system.	(SDL) CM 5.17 Ability to counsel mothers on breast feeding with focus on attachment to breast and correct position of the newborn	
02.30 – 03.30 P.M.	SDL (SEMINAR) Heart and Blood vessels		PRACTICALS MICRO/PATH/PHARM		PH8.3 Explain the kinetics, dynamics, adverse effects, indications of the following antibacterial drugs: Sulphonamides, Quinolones, Betalactams, Macrolides, Tetracyclines, Aminoglycosides, and newer antibacterial drugs (LGT)	PA13.1 Describe hematopoiesis and extra medullary hematopoiesis and the role of anticoagulants in hematology	
03.30 – 04.30 P.M.	FM2.5 Describe and discuss issues related to sudden natural deaths	of conditions to be us MI 3.7, 9.3 - Choose enteric fever based on the duration of illness. Pathology : PA13.3 Describe collectio	egible prescription and write rational prescriptions sed are given with other relevant competencies) (P the most appropriate laboratory test in a suspecte and in a suspected case of carrier Culture discuss Paratyphi B (SGT Case based discussion) on of specimens and identify coagulants and anticommon haematological tests – Hb, RBC count, WBC	//SGT/CBL) ed case of ion: Salmonella Typhi, Paratyphi A, agulant tubes, instruments	Immunology MI 2.1 to MI 2.8 (Theory assessment)	FM2.6 Describe and discuss natural and unnaturaldeaths	

	09-02-2026	10-02-2026	11-02-2026	12-02-2026	13-02-2026	14-02-2026	15-02-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
11.30 – 12.30 P.M.	ETIOLOGY AND CLASSIFICATION OF PNEUMONIA: GM 3.1: Define, discuss, describe and distinguish community acquired pneumonia nosocomial pneumonia and aspiration pneumonia. GM3.2:Discuss and describe the aetiologies of various kinds of pneumonia and their microbiology depending on the setting and Immune status of the host	PA14.1 Describe iron metabolism and Describe the etiology, investigations and differential diagnosis of microcytic hypochromic anemia	PH8.3 Explain the kinetics, dynamics, adverse effects, indications of the following antibacterial drugs: Sulphonamides, Quinolones, Betalactams, Macrolides, Tetracyclines, Aminoglycosides, and newer antibacterial drugs (Penicillins) (LGT)	MI 3.10 Describe the morphology, life cycle, pathogenesis, laboratory diagnosis, prevention and control of the common parasites causing anaemia (LGT)	PH8.3 Explain the kinetics, dynamics, adverse effects, indications of the following antibacterial drugs: Sulphonamides, Quinolones, Betalactams, Macrolides, Tetracyclines, Aminoglycosides, and newer antibacterial drugs (Macrolides, Lincosamides and Glycopeptides) (SGT)		
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.	PH8.3 Explain the kinetics, dynamics, adverse effects, indications of the following antibacterial drugs: Sulphonamides, Quinolones, Betalactams, Macrolides, Tetracyclines, Aminoglycosides, and newer antibacterial drugs (LGT)	MI 3.9 Enumerate the common infective causes of anaemia and describe the mechanisms involved in causing anaemia by them. (LGT)	PA15.1 Describe the metabolism of Vitamin B12 and the etiology and pathogenesis of B12 deficiency and describe laboratory investigations of macrocytic anemia PA15.2 Enumerate the differences and describe the etiology, laboratory features of megaloblastic anemia and distinguishing features of megaloblastic and non-megaloblastic macrocytic anemia	PH8.3 Explain the kinetics, dynamics, adverse effects, indications of the following antibacterial drugs: Sulphonamides, Quinolones, Betalactams, Macrolides, Tetracyclines, Aminoglycosides, and newer antibacterial drugs (Penicillins) (LGT)	PA16.1 Define and classify hemolytic anemia and describe the pathogenesis and clinical features and hematologic indices of hemolytic anemia		
02.30 – 03.30 P.M.	PA13.2 Define and classify anemia Enumerate and describe the investigation of anemia				PHB.3 Explain the kinetics, dynamics, adverse effects, indications of the following antibacterial drugs: Sulphonamides, Quinolones, Betalactams, Macrolides, Tetracyclines, Aminoglycosides, and newer antibacterial drugs (Macrolides, Lincosamides and Glycopeptides) (LGT)		
03.30 – 04.30 P.M.	FM2.7 Discuss moment of death, modes ofdeath–coma, asphyxia and syncope	PH10.6 Perform a critical apprais MI 3.8 Read and interpret the results of various laboral Pathology : PA13	MI 3.11.1 Morphology, life cycle, pathogenesis, clinical presentation, laboratory diagnosis and prevention: Kala Azar (LGT)				

	16-02-2026	17-02-2026	18-02-2026	19-02-2026	20-02-2026	21-02-2026	22-02-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	Microbiology Internal assessment 1- General Microbiology (1.1 to 1.13), Immunology (2.1 to 2.8), CVS (3.1 to 3.11)	
11.30 – 12.30 P.M.	SU 5.4 DISCUSS MEDICO LEGAL ASPECTS OF WOUNDS.	PA16.2 Describe the pathogenesis, features, hematologic indices and peripheral blood picture of thalassemia	PH8.3 Explain the kinetics, dynamics, adverse effects, indications of the following antibacterial drugs: Sulphonamides, Quinolones, Betalactams, Macrolides, Tetracyclines, Aminoglycosides, and newer antibacterial drugs (Miscellaneous and polypeptide antibiotics, Urinary Antiseptics) (SGT)	laboratory diagnosis and prevention:	PH8.5 Explain the types, kinetics, dynamics, therapeutic uses and adverse effects of drugs used in tuberculosis. Devise management plan for tuberculosis treatment in various categories. (LGT)	MI 3.13.2 Lab diagnosis, prevention and the principles of management of HIV (LGT)	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	
01.30 – 02.30 P.M.	PH8.3 Explain the kinetics, dynamics, adverse effects, indications of the following antibacterial drugs: Sulphonamides, Quinolones, Betalactams, Macrolides, Tetracyclines, Aminoglycosides, and newer antibacterial drugs(SGT)	MI 3.11.2 Morphology, life cycle, pathogenesis, clinical presentation, laboratory diagnosis and prevention: Malaria (LGT)	PA16.3 Describe the etiology, pathogenesis, hematologic indices and peripheral blood picture of Acquired hemolytic anemia and different hemolytic Anemia's PA17.1 Describe the etiology, pathogenesis and findings in aplastic Anemia and Enumerate the indications and describe the findings in bone marrow aspiration and biopsy	PH8.4 Devise a pharmacotherapeutic plan for UTI and STDs and explain to patient the instructions and adherence to treatment. (SGT/Seminar)	PA18.1 Enumerate and describe the causes of leukocytosis leucopenia lymphocytosis and leukemoid reactions	[SDL] CM 5.18 Ability to counsel mothers on complementary feeding using National guidelines while being sensitive of cultural and socioeconomic influences	
02.30 – 03.30 P.M.	PA16.2 Describe the pathogenesis, features, hematlogic indices and peripheral blood picture of sickle cell anemia	PRACTICALS MICRO/PATH/PHARM			PH8.5 Explain the types, kinetics, dynamics, therapeutic uses and adverse effects of drugs used in tuberculosis. Devise management plan for tuberculosis treatment in various categories. (SGT/CBL/SDL)	PA18.2 Describe the etiology, genetics, pathogenesis classification, features, hematologic features of acute and chronic leukemia	
03.30 – 04.30 P.M.	FM2.8 Describe and discuss suspended animation	PH10.3 To prepare and explain a list of P-drug	aria from agents of benign malaria reported in periph d discussion) seripheral smear in microcytic Anemia ood picture of macrocytic Anemia	MI 3.13.1 Epidemiology, etio- pathogenesis, evolution, complications- HIV (LGT)	FM2.9 Describe and discuss post-mortem changes including signs of death, cooling of body, post-mortem lividity, rigor mortis, cadaveric spasm, cold stiffening and heat stiffening		

	23-02-2026	24-02-2026	25-02-2026	26-02-2026	27-02-2026	28-02-2026	01-03-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	PCT 1 PATHOLOGY	
11.30 – 12.30 P.M.	skull	PA19.1 Enumerate the causes and describe the differentiating features of lymphadenopathy PA19.2 Describe the pathogenesis and pathology of tuberculous Lymphadenitis PA19.4 Enumerate and differentiate the causes of splenomegaly	PH 8.1-8.6 Chemotherapy I Tutorials	MI 3.3, 9.1 Dengue & Viral Haemorrhagic fever (LGT)	PH5.1 Devise management of various stages of Bronchial asthma, COPD. Explain salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for the management of Bronchial asthma, COPD and Rhinitis. (LGT)	MI 3.3, 9.1 Rickettsial infections (SGT)	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	
01.30 – 02.30 P.M.	PH8.6 Discuss the types, Kinetics, dynamics, adverse effects for drugs used for Leprosy and outline management of Lepra reactions (LGT)	MI 3.13.3 Opportunistic infections- HIV (SDL)	PA19.3 Describe and discuss the pathogenesis, pathology and the differentiating features of Hodgkin's and non-Hodgkin's lymphoma	PH5.2 Explain types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for cough management. Describe management of dry & productive cough (LGT)	Revision for PCT1	[SDL] CM 5.19 Assess the nutritional content of processed foods learning to understand labels, and empower patients to make informed nutritional decisions	
02.30 – 03.30 P.M.	PA18.2 Describe the etiology, genetics, pathogenesis classification, features, hematologic features of acute and chronic leukemia				PH5.1 Devise management of various stages of Bronchial asthma, COPD. Explain salient pharmacokinettics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for the management of Bronchial asthma, COPD and Rhinitis. (SGT/CBL/SDL)	PA19.3 Describe and discuss the pathogenesis, pathology and the differentiating features of Hodgkin's and non-Hodgkin's lymphoma	
03.30 – 04.30 P.M.	FM2.10 Describe putrefaction, mummification,adipocereandmaceration	PRACTICALS MICRO/PATH/PHARM Pharmacology - MENTORSHIP MI 3.13, 9.1 - HIV & Dengue - Virology exercises (SGT C Pathology : PA 19.6 Identify and describe the features Hematology slides - CML, CLL, AML, ALL HPE slide - Hodgkin Lymphoma		roscopic specimen	MI 10.1 Hospital acquired blood stream infections (LGT)	FM2.11 Discuss estimation of time since death	

	02-03-2026	03-03-2026	04-03-2026	05-03-2026	06-03-2026	07-03-2026	08-03-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CUNICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	Microbiology - AETCOM Module 2.1 & 2.8	
11.30 – 12.30 P.M.	CLINICAL FEATURES & COMPLICATIONS OF PNEUMONIA: GM3.3: Discuss and describe the pathogenesis, presentation, natural history and complications of pneumonia	PA20.2 Define and describe disseminated intravascular coagulation, its laboratory findings and diagnosis of disseminated intravascular coagulation and diagnosis of Vitamin K deficiency	PH3.2 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of different sedative and hypnotic agents and explain pharmacological basis of selection and use of different sedative and hypnotic agents (LGT)		PH3.3 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used in epilepsy and devise management plan for a case of uncontrolled seizure (Antiepileptic drugs - I) (LGT)	MI 7.1.2 Upper respiratory infections- Viral, fungal and Pararsitic agents Etiopathogenesis, clinical features lab diagnosis & prevention (LGT)	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	
01.30 – 02.30 P.M.	PH3.1 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of General anaesthetics, and preanaesthetic medications (LGT)	MI 3.3 Systemic fungal infections (LGT)	PA20.3 Define and describe its laboratory findings and diagnosis of Multiple Myeloma	PH3.2 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of different sedative and hypnotic agents and explain pharmacological basis of selection and use of different sedative and hypnotic agents (SGT/CBL)	PA21.1 Classify and describe blood group systems (ABO and RH) PA21.2 Enumerate blood components and describe their clinical uses PA21.5 Enumerate the indications and describe the principles and procedure of autologous transfusion	[SDL] CM 5.20 Counsel for diet modification for a diabetic/ hypertensive/obese individual	
02.30 – 03.30 P.M.	PA20.1 Describe normal hemostasis Classify and describe the etiology, pathogenesis and pathology of vascular and platelet disorders including ITP and hemophilia's				PH3.3 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used in epilepsy and devise management plan for a case of uncontrolled seizure (Antiepileptic drugs – II) (SGT/CBL/SDL)	PA21.3 Enumerate and describe infections transmitted by blood transfusion PA21.4 Describe transfusion reactions and enumerate investigation of a transfusion reaction	
03.30 – 04.30 P.M.	FM2:12 Introduction to mortuary setup and minimum requirement for conducting post-mortem examination and Embalming techniques	PRACTICALS MICRO/PATH/PHARM Pharmacology - PCT-1 (Practicals) Microbiology: MI 1.10, 7.5 Acid fast staining - E MI 7.1, 9.3 Influenza virus- Virology exercise (St Pathology: PA21.6 Describe the correct technic Practicals – Blood grouping and typing OSPE charts – Myeloma, Cross matching		MI 7.1.1 Upper respiratory infections- Bacterial agents- Etiopathogenesis, clinical features lab diagnosis & prevention (LGT)	FM2.13 Describe and discuss autopsy competencies including post-mortem examination, different types of autopsies, aims and objectives of post-mortem examination		

	09-03-2026	10-03-2026	11-03-2026	12-03-2026	13-03-2026	14-03-2026	15-03-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	AETCOM/ AITO/IA	
11.30 – 12.30 P.M.	SU 6.1 DEFINE AND DESCRIBE THE AETIOLOGY AND PATHOGENESIS OF SURGICAL INFECTIONS.	PA30.1 Classify and describe the types, etiology, pathogenesis, hormonal dependency of breast pathology and benign disease PA30.4 numerate and describe the etiology, hormonal dependency and pathogenesis of Gynaecomastia	PH3.4 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs of opioid analgesics and explain the special instructions for use of opioids.(Opioids - II) (SGT/CBL/SDL)	MI 7.2.2 Lower respiratory infections- Mycobacterial agents- Etiopathogenesis, clinical features lab diagnosis & prevention (LGT)	PH IA VIVA (CVS, Blood)	MICRO	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	
01.30 – 02.30 P.M.	PH3.4 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs of opioid analgesics and explain the special instructions for use of opioids.(Opioids - I) (LGT)	MI 7.2.1 Lower respiratory infections- Bacterial agents- Etiopathogenesis, clinical features lab diagnosis & prevention (LGT)		PH IA (CVS, Blood)	PA29.1 Describe the epidemiology, pathogenesis, etiology, pathology, screening, diagnosis and progression of carcinoma of the cevix PA29.6 Describe the etiology and morphologic features of cervicitis		
02.30 – 03.30 P.M.	- Seminar/SDL - Hematology	PRACTICALS MICRO/PATH/PHARM			PH3.5 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for depression and devise management plan for depressive disorders (Antidepressants) (LGT/CBL)	РАТН	
03.30 – 04.30 P.M.	FM2.14 Describe the legal requirements to conduct post-mortem examination and competencies to conduct medicolegal post- mortem examination	PH10.2 Perform a critical evaluation of the drug promot PH10.1 Compare and contrast different sources of drug Microbiology: MI 1.10, 7.5 - Acid fast staining I (DOAP) - Pathology: PA30.5 Describe and identify the morpholog Cytology and HPE – Fibroadenoma, CA breast HPE - Phyllodes tumor Gross - Fibroadenoma, CA breast	information and update on latest information on drug & MI 7.3, 9.3 - Culture discussion- Klebsiella pneumonia	s (P/SGT) ae (SGT case based discussion)	MI 7.2.3 Lower respiratory infections- Viral & Parasitic agents- Etiopathogenesis, clinical features lab diagnosis & prevention (LGT)	SPORTS/FM	

	16-03-2026	17-03-2026	18-03-2026	19-03-2026	20-03-2026	21-03-2026	22-03-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	AETCOM/ AITO/IA	
	OG 13.1 Physiology of normal labour, machanism of labour, conduct of labour and management of third state of labour	pathology, diagnosis and progression and spread of carcinoma of the endometrium	PH3.6 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used in anxiety disorders. Discuss about general goals of Pharmacotherapy for the management of above disorders (LGT/CBL)	MI 7.3 Enlist & identify the etiological agents of lower respiratory infection in specific situations like age, immune status, community-acquired pneumonia, hospital-acquired pneumonia etc (LGT Case based discussion)	PHARM	MICRO	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	
01.30 – 02.30 P.M.	PH3.5 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for depression and devise management plan for depressive disorders (Antimaniac drugs) (LGT/CBL)	MI 7.2.4 Fungal respiratory tract infections (SGT)	PA29.4Classify and describe the etiology, pathogenesis, pathology, morphology, clinical course, spread and complications of ovarian tumors	PH3.7 Explain types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for Parkinsonism and other neurodegenerative disorders. Write a prescription to manage a case of drug induced parkinsonism (LGT/CBL)	РАТН	см	
02.30 – 03.30 P.M.	PA29.7 Describe the etiology, hormonal dependence, features and morphology of endometriosis PA29.8 Describe the etiology and morphologic features of adenomyosis PA29.9 Describe the etiology, hormonal dependence and morphology of endometrial hyperplasia				PHARM	РАТН	
03.30 – 04.30 P.M.	FM2.15 Describe and discuss obscure autopsyandVirtopsy	poisoning Microbiology: MI 1.10, 7.5 Acid fast staining II (DOAP)		p.fumigatus, Asp.niger (SGT case based discussion)		SPORTS/FM	

	23-03-2026	24-03-2026	25-03-2026	26-03-2026	27-03-2026	28-03-2026	29-03-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	Microbiology AITO- Anaemia	
11.30 – 12.30 P.M.	MANAGEMENT OF PNEUMONIA: GM3.17 Describe and enumerate the indications for hospitalization in patients with pneumonia GM3.18: Describe and enumerate the indications for isolation and barrier nursing in patients with pneumonia GM3.19: Describe and discuss the supportive therapy in patients with pneumonia including oxygen use and indications for ventilation		PH3.8 Identify and manage methanol poisoning and chronic ethanol Intoxication (Alcohols) (SGT/Seminar)	MI 10.1 Enumerate different causative agents and the types of Healthcare-Associated Infections (HAI). Define HAI and describe the chain of transmission and its role in preventing HAI (LGT)	PH8.7 Discuss the types, Kinetics, dynamics, adverse effects of drugs used for following Protozoal / Vector borne diseases: 1. Amoebiasis 2. Kala-azar 3. Malaria 4. Filariasis (LGT)	MI 10.2 Describe the standard & transmission based precautions for infection control and the role of the hospital infection control committee (HICC) in the prevention of HAI. (LGT)	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	
01.30 – 02.30 P.M.	PH3.7 Explain types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for Parkinsonism and other neurodegenerative disorders. Write a prescription to manage a case of drug induced parkinsonism (Drugs for Alzheimer's Disease) (SGT/CBL)	MI 7.1 Ear infections (SGT)	PA25.1 Define and describe the etiology, types, pathogenesis, stages, morphology and complications of pneumonia	PH3.9 Describe the drugs that are abused and cause addiction (dependence, addiction, stimulants, depressants, psychedelics, drugs used for criminal offences). (SGT/PBL)	PA25.2 Describe the etiology, gross and microscopic appearance and complications of lung abscess	[SDL] CM20.1 List Importantpublic health eventsof last five years CM20.2 Describe various issues during outbreaks and their prevention	
02.30 – 03.30 P.M.	PA29.4Classify and describe the etiology, pathogenesis, pathology, morphology, clinical course, spread and complications of ovarian tumors	PRACTICALS MICRO/PATH/PHARM			PH8.7 Discuss the types, Kinetics, dynamics, adverse effects of drugs used for following Protozoal / Vector borne diseases: 1. Amoebiasis 2. Kala-azar 3. Malaria 4. Filariasis (LGT)	IA 3 – Heart, Blood vessels, MGT, FGT, Breast	
03.30 – 04.30 P.M.	FM2.16 Describe and discuss examination of clothing, preservation of viscera on post-mortem examination for chemical analysis and other medicolegal purposes, post-mortem artefacts	PH 10.4 Describe parts of a correct, rational ar (examples of conditions to be used are given w Microbiology: MI 10.3 PPE - Donning & Doffin MI 11.1 Interpretation of AST (DOAP) Pathology: PA29.1 Describe and identify the Gross- Leiomyoma uterus, CA endometrium, S HPE – Teratoma ovary, Products of conception	with other relevant competencies) (P/SGT/CBL g & norphologic and microscopic features of disea erous/Mucinous tumors, Teratoma ovary		Cardiovascular system & Bloodstream infections (MI 3.1 to 3.13), Respiratory system (7.1 to 7.3) (Theory assessment)	FM2.17 Describe the clinical features, post- mortem finding and medico legal aspects of injuries due to physical agents like heat (heat-hyper pyrexia, heat stroke, sun stroke, heat exhaustion/prostration, heat cramps [miner's cramp] or cold (systemic and localized hypothermia, frostbite, trench foot, immersion foot)	

	30-03-2026	31-03-2026	01-04-2026	02-04-2026	03-04-2026	04-04-2026	05-04-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	PHARM AETCOM 2.2	
11.30 – 12.30 P.M.	SU 6.2 ENUMERATE PROPHYLACTIC AND THERAPEUTIC ANTIBIOTICS PLAN APPROPRIATE MANAGEMENTS.	РАТН	PH8.8 Explain the types, kinetics, dynamics, adverse effects of drugs used for fungal infections (SGT/CBL)	MI 10.5 Describe the commonly detected drug-resistant microbes in HAI. Explain the mechanism of evolution, spread, and control of antimicrobial drug resistance in hospitalized patients. (SGT)	PHARM	MI 1.1, 10.2 Quality assurance in Microbiology- NABL, EQAS, ICP in NABH (LGT)	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	
	PH8.7 Discuss the types, Kinetics, dynamics, adverse effects of drugs used for following Protozoal / Vector borne diseases: 1. Amoebiasis 2. Kala-azar (other antiprotozoal) 3. Malaria 4. Filariasis(SGT)	MICRO	PA25.3 Define and describe the etiology, types, pathogenesis, stages morphology and complications and evaluation of Obstructive airway disease (OAD) and bronchiectasis	PH8.9 Discuss the types, kinetics, dynamics, adverse effects of drugs used for Intestinal Helminthiasis (SGT)	PATH	[SDL] CM 20.3 Describe any event important to Health of the Community CM 20.4 Demonstrate awareness about laws pertaining to practice of community medicine	
02.30 – 03.30 P.M.	PA25.3 Define and describe the etiology, types, pathogenesis, stages morphology and complications and evaluation of Obstructive airway disease (OAD) and bronchiectasis	PRACTICALS MICRO/PATH	H/PHARM		PHARM	PA25.4 Define and describe the etiology, types, pathogenesis, stages, morphology microscopic appearance and complications of tuberculosis	
03.30 – 04.30 P.M.	FM2.18 Describe types of injuries, clinical features, patho- physiology, post	renal or hepatic dysfunct Microbiology: MI 6.3 Ider findings and culture repo	ion.(SGT/CBL) ntify the microbial agents causing meningitis from a Grar rt of CSF to diagnose a case of bacterial, viral, fungal or p fy and describe the features of diseases and tumors of lu Blung 18.		MICRO	FM2.19 Describe and discuss clinical features, post-mortem findings and medico-legal aspects of death due to starvation and neglect	

	06-04-2026	07-04-2026	08-04-2026	09-04-2026	10-04-2026	11-04-2026	12-04-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	
08.00 – 11.00 A.M.			CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
	OG 17.1 Physiology of lactation OG 17.3 Clinical features, diagnosis, and management of Mastitis and breast abscess	PA25.5 Define and describe the etiology, types, exposure, environmental influence, pathogenesis, stages, morphology, microscopic appearance and complications of Occupational lung disease	PH8.10 Discuss the types, kinetics, dynamics, adverse effects, indications and contraindications of drugs used for viral diseases including HIV (Antiviral agents) (LGT)	MI 6.1, 6.2 Viral Meningitis & Encephalitis- Etiopathogenesis, clinical features and Lab diagnosis (LGT)	PH IA CNS-Viva		
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.	PH 3.1-3.9 Tutorials -CNS	MI 6.1, 6.2 Bacterial Meningitis & Encephalitis- Etiopathogenesis, clinical features and Lab diagnosis (LGT)	PA25.6 Define and describe the etiology, types, exposure, genetic environmental influence, pathogenesis, stages, morphology, microscopic appearance, metastases and complications of tumors of the lung and pleura including mesothelioma	PH IA (CNS)	SDL/Revision RS		
02.30 – 03.30 P.M.	PA25.5 Define and describe the etiology, types, exposure, environmental influence, pathogenesis, stages, morphology, microscopic appearance and complications of Occupational lung disease	PRACTICALS MICRO/PATH/PHARM			PH8.10 Discuss the types, kinetics, dynamics, adverse effects, indications and contraindications of drugs used for viral diseases including HIV (Antiretroviral agents) (LGT/CBL/SDL)		
03.30 – 04.30 P.M.	FM 2.20 Describe special protocols for conduction of medico- legal autopsies in cases of death in custody or following	PH1.13 Identify and describe the management of drug in Microbiology: MI 6.3 Identify the microbial agents causin of CSF to diagnose a case of bacterial, viral, fungal or par MI 9.1 Rabies - Virology exercise (SGT case discussion)	ng meningitis from a Gram stained given smear. Read & Interpr		MI 6.1, 6.2 Parasitic CNS infections (SGT)		

	13-04-2026	14-04-2026	15-04-2026	16-04-2026	17-04-2026	18-04-2026	19-04-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	AITO Pathology Ischemic Heart Disease	
11.30 – 12.30 P.M.	ACUTE DIARRHEA: GM16.1 - Describe and discuss the aetiology of acute and chronic diarrhea including infectious and non infectious causes GM16.2 - Describe and discuss the acute systemic consequences of diarrhea including its impact on fluid balance GM16.13 - Describe and enumerate the indications, pharmacology and side effects of pharmacotherapy for parasitic causes of diarrhea GM16.14 - Describe and enumerate the indications, pharmacotherapy for bacterial and viral diarrhea	РАТН	PH 8.7-8.10 Tutorials	MI 6.1, 6.2 Fungal CNS infections (LGT)	PH8.11 Describe the types, kinetics, dynamics, adverse effects, indications and contraindications of anti-cancer drugs. Devise plan for amelioration of anticancer drug induced toxicity. (Cytotoxic agents) (LGT)	MI 9.1 Rabies (LGT)	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	
01.30 – 02.30 P.M.	PH8.10 Discuss the types, kinetics, dynamics, adverse effects, indications and contraindications of drugs used for viral diseases including HIV (Antiretroviral agents) (SGT/CBL)	MICRO	PA28.2 Describe the pathogenesis, pathology, presenting and distinguishing features, diagnostic tests, progression and spread of carcinoma of the penis	PH8.11 Describe the types, kinetics, dynamics, adverse effects, indications and contraindications of anti-cancer drugs. Devise plan for amelioration of anticancer drug induced toxicity. (Introduction to cancer chemotherapy) (LGT)	hyperplasia	[SDL] CM 13.5 Able to understand the management of handing a disaster in a simulated environment	
02.30 – 03.30 P.M.	PA28.1 Classify testicular tumors and describe the pathogenesis, pathology, presenting and distinguishing features, diagnostic tests, progression and spread of testicular tumors	PRACTICALS MICRO/P.	ATH/PHARM		PH8.11 Describe the types, kinetics, dynamics, adverse effects, indications and contraindications of anti-cancer drugs. Devise plan for amelioration of anticancer drug induced toxicity. (Hormonal and Target chemotherapy) (LGT)	PA28.4 Describe the pathogenesis, pathology, hormonal dependency presenting and distinguishing features, diagnostic tests, progression and spread of carcinoma of the prostate	
03.30 – 04.30 P.M.	or fragments,	condition. (examples of Microbiology: MI 1.10	r, BPH	ant competencies) (P/SGT/CBL)	MI 5.1 Tetanus (SGT)	FM2.22 Describe and discuss exhumation	

	20-04-2026	21-04-2026	22-04-2026	23-04-2026	24-04-2026	25-04-2026	26-04-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	PHARM AETCOM 2.3, 2.5	
11.30 – 12.30 P.M.	SU 7.1 DESCRIBE THE PLANNING AND CONDUCTS OF SURGICAL AUDIT.		PH6.2 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of prokinetics & drugs used for emesis and antiemetics. (SGT/CBL)	MI 6.2 Encephalitis (SDL)	PH6.4 Describe salient pharmacokinetics, pharmacodynamics, adverse drug reactions of drugs used for the management of constipation and devise management plan for a case of constipation (SGT/Seminar)	MI 11.2 Antimicrobial spectrum of important human pathogens along with its intrinsic & acquired drug resistance and its application in clinical therapy. (LGT)	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	
01.30 – 02.30 P.M.	PH6.1 Explain types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used in Acid peptic diseases including Peptic Ulcers, GERD and devise a management plan for a case of peptic ulcer. (SGT/CBL)	MI 6.1 Meningitis (SGT case based discussion)	PA27.1 Describe the normal histology of the kidney PA27.2 Define, classify and distinguish the clinical syndromes and describe the etiology, pathogenesis, pathology, morphology, clinical and laboratory and urinary findings, complications of renal failure PA27.3 Define and describe the etiology, precipitating factors, pathogenesis, pathology, laboratory urinary findings, progression and complications of acute renal failure PA27.4 Define and describe the etiology, precipitating factors, pathogenesis, pathology, laboratory urinary findings progression and complications of chronic renal failure	PH6.3 Describe salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for the management of diarrhoea and devise pharmacotherapeutic plan to manage acute and chronic diarrhoea in adults and children.(LGT/PBL/SDL)		[SDL] CM 14.4 Able to segregate the various hospital waste	
02.30 – 03.30 P.M.	PA34.1 Describe the etiology, types and CSF findings in meningitis pathogenesis, differentiating factors,				PHARM -MENTORSHIP	PA27.5 Define and classify glomerular diseases. Enumerate and describe the etiology, pathogenesis, mechanisms of glomerular injury, pathology, distinguishing features and clinical manifestations of glomerulonephritis	
03.30 – 04.30 P.M.	FM2.23 Crime Scene Investigation: Describe and discuss the objectives of crime scene visit, the duties & responsibilities of doctors on crime scene and the reconstruction of sequence of events after crime scene investigation	Microbiology: MI 7.5 Acid fast st Pathology: HPE- Schwannoma, I	a list of P-drugs for a given case/condition (P/SGT/CBL) aining- Certifiable skill & Interpretation of AST - OSPE (Practical ass		MI 1.1 Ocular infections (SGT)	FM2.24 Investigation of anaesthetic, operativedeaths: Describe and discuss special protocols for conduction of autopsy and for collection, preservation and dispatch of related material evidences	

	27-04-2026	28-04-2026	29-04-2026	30-04-2026	01-05-2026	02-05-2026	03-05-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	Microbiology AITO- Tuberculosis	
11.30 – 12.30 P.M.	OG 19.1 Physiology of puerperium, complications during puerperium and its diagnosis and management	PA27.6 Define and describe the etiology, pathogenesis, pathology, laboratory, urinary findings, progression and complications of IgA nephropathy	PHS.1,5.2 (RS), 6.1-6.5 (GIT) Tutorials	MI 8.1 Describe the etiopathogenesis and discuss the laboratory diagnosis of common bacterial, viral, fungal and parasitic infections of the genitourinary system (LGT)	PHARM	MI 8.2 Enlist common sexually transmitted infections (STI). Explain the pathogenesis, laboratory diagnosis and prevention of common bacterial and viral sexually transmitted infections. (LGT)	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	
01.30 – 02.30 P.M.	PH6.5 Describe salient pharmacokinetics, pharmacodynamics, adverse drug reactions of drugs used for the management of Inflammatory Bowel Disease and Irritable Bowel Disorders (SGT/Seminar)	MI 11.3 Explain the concept and application of the antimicrobial stewardship program including rational antimicrobial prescription and your role in its implementation. (SGT)	PA27.7 Enumerate and describe the findings in glomerular manifestations of systemic disease	PH7.4 Describe the types, mechanisms of action, adverse effects, indications and contraindications of the drugs which modify the release of Anterior Pituitary Hormones (LGT)	PATH	(SDL) CM3.5 Describe the standards of housing and the effect of housing on health	
02.30 – 03.30 P.M.	PA27.5 Define and classify glomerular diseases. Enumerate and describe the etiology, pathogenesis, mechanisms of glomerular injury, pathology, distinguishing features and clinical manifestations of glomerulonephritis				PHARM	PA27.8 Enumerate and classify diseases affecting the tubular interstitium PA27.9 Define and describe the etiology, pathogenesis, pathology, laboratory, urinary findings, progression and complications of acute tubular necrosis	
03.30 – 04.30 P.M.	FM2.25 Demonstrate professionalism while conducting autopsy in medico legal situations, interpretation of findings and making inference/opinion, collection preservation and dispatch of biological or trace evidences PRACTICALS MICRO/PATH/PHARM PH10.2 Perform a critical evaluation of the drug promotional literature and Interpret the package insert information contained in the drug package (P/SGT) Microbiology: MI 10.3 Hand hygiene & Biomedical waste management- Certifiable skill (Practical assessment) Pathology: Urine Analysis – Physical, Chemical and microscopic examination MI MI MI MI MI MI MI MI MI M				MICRO	FM2. 26 Demonstrate ability to work in a teamforconductionofmedico-legal autopsies in cases of death following alleged negligence medical dowry death, death in custody or following violation of human rights as per National Human Rights Commission Guidelines on exhumation	

	04-05-2026	05-05-2026	06-05-2026	07-05-2026	08-05-2026	09-05-2026	10-05-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS		CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
11.30 – 12.30 P.M.	CHRONIC DIARRHEA GM16.3 - Describe and discuss the chronic effects of diarrhea including malabsorption GM16.12 - Enumerate and discuss the indications for further investigations including antibodies, colonoscopy, diagnostic imaging and biopsy in the diagnosis of chronic diarrhea	PA27.11 Define classify and describe the etiology, pathogenesis pathology, laboratory, urinary findings, distinguishing features progression and complications of vascular disease of the kidney	PH7.3 Describe the types, kinetics, dynamics, adverse drug reactions of drugs used in thyroid Disorders and devise a management plan for a case with thyroid Disorder.(LGT/CBL/SDL)	MI 8.3 Concept and utility of Syndromic management of STI (SDL)	PH IA Viva (Chemotherapy)		
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.	PH7.3 Describe the types, kinetics, dynamics, adverse drug reactions of drugs used in thyroid Disorders and devise a management plan for a case with thyroid Disorder.(LGT/CBL)	Central Nervous system- MI 6.1 to 6.3 (Theory assessment)	PA27.12 Define classify and describe the genetics, inheritance, etiology, pathogenesis, pathology, laboratory, urinary findings, distinguishing features, progression and complications of cystic disease of the kidney	PH IA (Chemotherapy)	PA27.13 Define classify and describe the etiology, pathogenesis, pathology, laboratory, urinary findings, distinguishing features progression and complications of renal stone disease and obstructive uropathy		
02.30 – 03.30 P.M.	PA27.10 Describe the etiology, pathogenesis, pathology, laboratory findings, distinguishing features progression and complications of acute and chronic pyelonephritis and reflux nephropathy				PH7.1 Describe the types, kinetics, dynamics, adverse drug reactions of drugs used in diabetes mellitus and devise management for an obese and non-obese diabetic patient & also comment on prevention of complications of the diabetes. (Insulin)(LGT/CBL/SDL)		
03.30 – 04.30 P.M.	FM2.27 Demonstrate ability to exchange informationbyverbal,ornonverbal communication to the peers, family members, law enforcing agency and judiciary		ı prescription and suggest ways to improve it (P/SGT/CI Escherichia coli, Proteus mirabilis (SGT case discussion al and microscopic examination		MI 8.4 Etiopathogenesis, clinical course, and the appropriate method for specimen collection and laboratory diagnosis of different clinical and epidemiological types of urinary tract infections (LGT)		

	11-05-2026	12-05-2026	13-05-2026	14-05-2026	15-05-2026	16-05-2026	17-05-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	AETCOM - Pathology AETCOM 2.4 AETCOM 2.7	
11.30 – 12.30 P.M.	SU 7.2 DESCRIBE THE PRINCIPLES AND STEPS OF CLINICAL RESEARCH IN GENERAL SURGERY.	PA27.15 Describe the etiology, genetics, pathogenesis, pathology, presenting features and progression of thrombotic angiopathies	PH7.5 Explain the types, kinetics, dynamics, adverse effects, indications and contraindications of corticosteroids and communicate to patient the appropriate use of corticosteroids (LGT)	MI 4.1 Define and differentiate between diarrhea, dysentery and food poisoning. Enumerate the microbial agents causing them (LGT)	PH7.6 Describe the types, kinetics, dynamics, adverse effects, indications and contraindications of Androgens and drugs used of Erectile Dysfunction (LGT)	MI 4.2.2 Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of viral, parasitic & fungal agents causing diarrhoea (LGT)	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	
01.30 – 02.30 P.M.	PH7.1 Describe the types, kinetics, dynamics, adverse drug reactions of drugs used in diabetes mellitus and devise management for an obese and non-obese diabetic patient & also comment on prevention of complications of the diabetes. (Oral antidiabetic agents) (LGT/CBL/SDL)		PA27.16 Describe the etiology, genetics, pathogenesis, pathology, presenting features and progression of urothelial tumors	PH7.5 Explain the types, kinetics, dynamics, adverse effects, indications and contraindications of corticosteroids and communicate to patient the appropriate use of corticosteroids (LGT)	PA23.1 Describe the etiology, pathogenesis, pathology and clinical features of oral cancers	(SDL) CM 3.8 Describe the mode of action, application cycle of commonly used insecticides and rodenticides	
02.30 – 03.30 P.M.	PA27.14 Classify and describe the etiology, genetics, pathogenesis, pathology, presenting features, progression and spread of renal tumors				PH7.7 Explain the types, kinetics, dynamics, adverse effects, indications and contraindications of drugs which modify Female Reproductive Functions including contraceptives. Explain the important instruction for use of female and male contraceptives Estrogen & AntiEstrogens (LGT)	SDL Kidney	
03.30 – 04.30 P.M.	FM2.28 Demonstrate ability to use local resourceswhenever required like in mass disaster situations	PRACTICALS MICRO/PATH/PHARM PH 10.4 Describe parts of a correct, rational a conditions to be used are given with other rel Microbiology: MI 1.10, 4.4 Stool microscopy - Pathology: HPE – CPN, RCC, SCC GROSS – CPN, RCC Cytology/HPE – Pleomorphic adenoma		MI 4.2.1 Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of bacterial agents causing diarrhoea (LGT)	FM3.1 Define, classify and describe asphyxia and medico-legal interpretation of post-mortem findings in asphyxial deaths		

	18-05-2026	19-05-2026	20-05-2026	21-05-2026	22-05-2026	23-05-2026	24-05-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
	OG 20.1 Discussion of Legal aspect, indications and methods of first trimester and second trimester MTP, Complications of MTP and its management	PA23.2 Describe the etiology, pathogenesis, pathology, microbiology, clinical and microscopic features of carcinoma esophagus	PH7.7 Explain the types, kinetics, dynamics, adverse effects, indications and contraindications of drugs which modify Female Reproductive Functions including contraceptives. Explain the important instruction for use of female and male contraceptives (SGT/SDL)	MI 4.3.1 Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of bacterial agents causing dysentery (LGT	PH7.9 Describe drugs used for treatment of Infertility (LGT/PBL)		
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
	PH7.7 Explain the types, kinetics, dynamics, adverse effects, indications and contraindications of drugs which modify Female Reproductive Functions including contraceptives. Explain the important instruction for use of female and male contraceptivesProgestins & AntiProgestins (LGT)	Genitourinary system- MI 8.1 to 8.4 (Theory assessment)	PA23.3 Describe the etiology, pathogenesis, pathology, microbiology, clinical and microscopic features of peptic ulcer disease	PH7.8 Explain the types, kinetics, dynamics, adverse effects, indications and contraindications of uterine relaxants and stimulants. (SGT)	Pathology Case Based Learning - CA Esophagus and Peptic ulcer disease		
02.30 – 03.30 P.M.	IA4 – RS, Kidney, GUT, CNS				PH7.2 Describe the types, kinetics, dynamics, therapeutic uses, adverse drug reactions of drugs used in osteoporosis and devise management plan for a female and male patient with osteoporosis. (LGT/CBL/SDL)		
03.30 – 04.30 P.M.	PRACTICALS MICRO/PATH/PHARM PH1.12 Define Pharmacovigilance its principles and demonstrate ADR reporting (SGT/CBL) Microbiology: MI 1.10, 4.4 Stool microscopy - I (DOAP) & MI 4.2, 4.3, 9.3 Culture discussion-Vibrio cholerae, Shigella (SGT case discussion) including clinical findings and medico-legal aspects of death due to hanging and strangulation including examination, preservation and dispatch of ligature material PRACTICALS MICRO/PATH/PHARM PH1.12 Define Pharmacovigilance its principles and demonstrate ADR reporting (SGT/CBL) Microbiology: MI 1.10, 4.4 Stool microscopy - I (DOAP) & MI 4.2, 4.3, 9.3 Culture discussion-Vibrio cholerae, Shigella (SGT case discussion) Pathology: IA Practicals MI 4.3.2 Describe the epidemiology, morpholog pathogenesis, clinical features and diagnostic nor vivral, fungal & parasitic agents causing dyser (LGT) (LGT)						

	25-05-2026	26-05-2026	27-05-2026	28-05-2026	29-05-2026	30-05-2026	31-05-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.							
11.30 – 12.30 P.M.							
12.30 – 01.30 P.M.							
01.30 – 02.30 P.M.							
02.30 – 03.30 P.M.							
03.30 – 04.30 P.M.							

	01-06-2026	02-06-2026	03-06-2026	04-06-2026	05-06-2026	06-06-2026	07-06-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	PCT 2 PH (CVS, Blood, CNS, Chemotherapy)	
11.30 – 12.30 P.M.	HEADACHE GM17.1-Define and classify headache and describe the presenting features, precipitating factors, aggravating and relieving factors of various kinds of headache GM17.2-Elicit and document and present an appropriate history including aura, precipitating aggravating and relieving factors, associated symptoms that help identify the cause of headaches	PA23.5 Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine and appendicitis.	PH 4.1-4.4,4.11 Blood Tutorials	MI 4.6 Describe the infective aetiology, pathogenesis and clinical course of Acid peptic disease (APD) and Discuss the laboratory diagnosis and management of the causative agent of APD. (SDL)	PH 8.1-8.6 Chemotherapy 1 Tutorials	MI 4.7.2 Describe the epidemiology, etiopathogenesis, clinical features and complications of viral hepatitis (Blood borne viruses) (LGT)	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	
01.30 – 02.30 P.M.	PH 4.5-4.10 CVS Tutorials	MI 4.5 Enumerate the bacterial, viral, parasitic and fungal agents of food poisoning and discuss their pathogenesis, clinical course and laboratory diagnosis.	PA23.6 Describe and etiology and pathogenesis and pathologic and distinguishing features of Inflammatory bowel disease	PH 3.1-3.9 CNS Tutorials	PA23.7 Enumerate causes and describe laboratory diagnosis of malabsorption syndrome	MI 4.8.1 Discuss the modalities in laboratory diagnosis of viral hepatitis caused by hepatitis viruses with special emphasis on viral markers (LGT)	
02.30 – 03.30 P.M.	PA23.4 Describe and etiology and pathogenesis and pathologic features of carcinoma of the stomach	PRACTICALS MICRO/PATH/PHARM			PH 8.7 - 8.11 Chemotherapy 2 Tutorials	PA23.8 Describe the etiology, pathogenesis, pathology and distinguishing features of carcinoma of the colon	
03.30 – 04.30 P.M.	FM3.3 Describe and discuss patho-physiology, clinical features, post mortem findings and medicolegal aspects of traumatic asphyxia, obstruction of nose & mouth, suffocation and sexual asphyxia	on drugs; PH10.14 Communicate with the contraceptives, anti TB drugs etc. (P/SGT) F prescribing for controlled drugs, off-label in	patient regarding optimal use of a drug ther PH10.5 Identify and apply the legal and ethinedicines, and prescribing for self, close fan by - II (DOAP) & MI 4.2, 9.3 Rotaviruses - Viru		MI 4.7.1 Describe the epidemiology, etiopathogenesis, clinical features and complications of viral hepatitis (Enterically transmitted) (LGT)	FM3.4 Describe and discuss types, patho- physiology, clinical features, postmortem findings and medico-legal aspects of drowning	

	08-06-2026	09-06-2026	10-06-2026	11-06-2026	12-06-2026	13-06-2026	14-06-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
11.30 – 12.30 P.M.	SU 8.1 DESCRIBE THE PRINCIPLES OF ETHICS AS IT PERTAINS TO GENERAL SURGERY.	PA31.7 Describe the etiology, pathogenesis, manifestations, laboratory, morphologic features, complications and metastases of pancreatic cancer	PH9.2 Describe management of common drug poisonings, insecticides, common stings and bites (SGT/Seminar)	MI 4.9 Suggest the most appropriate laboratory test based on history and clinical presentation in a suspected case of viral hepatitis and interpret the type and progress of viral hepatitis based on the laboratory report of viral markers in a case of infection by hepatitis virus. (SDL)	PH9.4 Describe basics of vaccine use and types of		
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.	PCT-2 Viva PH (CVS, Blood, CNS, Chemotherapy)	MI 4.8.2 Preventive strategies for viral hepatitis caused by hepatitis viruses. (SGT)	GIT Revision	PH9.2 Describe management of common drug poisonings, insecticides, common stings and bites (SGT/Seminar)	SDL PA24.1 Describe Bilirubin metabolism, enumerate the etiology and pathogenesis of jaundice, distinguish between direct and indirect hyper Bilirubinemia		
02.30 – 03.30 P.M.	PA23.8 Describe the etiology, pathogenesis, pathology and distinguishing features of carcinoma of the colon				PH9.4 Describe basics of vaccine use and types of vaccines (SGT/Seminar)		
	FM4.1 Define and describe Corpus Delicti, establishment of identity of living persons including race, sex, religion, complexion, stature.	PRACTICALS MICRO/PATH/PHARM Pharmacology - PCT-2 (Practicals) Microbiology: MI 4.8, 9.3 - HBsAg, Anti HCV Ab- Virology Pathology: HPE – CA colon Gross – CA colon, Polyps of colon OSPE charts / Case based learning – CA colon, Polyposis		MI 10.4 Describe the methods used and significance of assessing the microbial contamination of food, milk, water and air (in hospital surveillance) (LGT)			

	15-06-2026	16-06-2026	17-06-2026	18-06-2026	19-06-2026	20-06-2026	21-06-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	MICROBIOLOGY- Internal assessment 2 - RS, CNS, Genitourinary system, GIT and HBT, HAI, AMS & AMR (Theory assessment)	
11.30 – 12.30 P.M.	OG 23.1 Physiology of puberty, features of abnormal puberty, common problems and their management	clinical and laboratory	PH9.5 Describe types, precautions and uses of antiseptics and disinfectants (SGT/Seminar)	(SGT)	PH9.7 Describe drugs used in glaucoma and other ocular disorders including topical (ocular) drug delivery systems (Ocular Pharmacology)	MI 9.1.2 Explain etio-pathogenesis, vectors, clinical course, transmission, risk factors, laboratory diagnosis, and preventive & control strategies of different zoonotic infections caused by viral agents. (LGT)	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	
01.30 – 02.30 P.M.	PH9.3 Describe chelating agents and make a plan for management of heavy metal poisoning (SGT/Seminar)	MI 1.1 Infections of the oral cavity (SGT)	PA24.3 Describe the etiology and pathogenesis of viral and toxic hepatitis: distinguish the causes of hepatitis based on the clinical and laboratory features. Describe the pathology, complications and consequences of hepatitis	PH9.6 Describe drugs used in various skin disorders like acne vulgaris, scabies, pediculosis, psoriasis including sunscreens (SGT/Seminar)	PA24.4 Describe the pathophysiology, pathology and progression of alcoholic liver disease including cirrhosis		
02.30 – 03.30 P.M.	PA24.2 Describe the pathophysiology and pathologic changes seen in hepatic failure and their clinical manifestations, complications and consequences	PRACTICALS MICRO/PATH/PHARM			PHARM -MENTORSHIP	PA24.5 Describe the etiology, pathogenesis and complications of portal hypertension	
03.30 – 04.30 P.M.	FM4.2 Discuss teeth-eruption, decay, bite marks, and medico-legal aspects of teeth.	pharmacotherapy; PH10.16 Demonstrate an und line of management; PH10.17 Demonstrate abilit OTC drugs	e to treatment and motivate patients with chronic erstanding of the caution in prescribing drugs like y to educate public & patients about various aspe Aucor, Candida, Cryptococcus (Culture discussion) roscopic features of liver diseases and tumors	ly to produce dependence and recommend the ccts of drug use including drug dependence and (SGT case based discussion)	MI 9.1.1 Define and classify Zoonotic infections. Explain etio-pathogenesis, vectors, clinical course, transmission, risk factors, laboratory diagnosis, and preventive & control strategies of different zoonotic infections caused by bacterial agents. (LGT)	FM4.3 Discuss age determination using morphology, bones- ossification centers and medico-legal aspects of age.	

	22-06-2026	23-06-2026	24-06-2026	25-06-2026	26-06-2026	27-06-2026	28-06-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		PCT2 PATHOLOGY	
11.30 – 12.30 P.M.	MIGRAINE GM17.3 - Classify migraine and describe the distinguishing features between classical and non classical forms of migraine GM17.11 - Describe the indications, pharmacology, dose, side effects of abortive therapy in migraine GM17.12 - Describe the indications, pharmacology, dose, side effects of prophylactic therapy in migraine	PA 24.8 Describe the pathophysiology, pathology and complications of acute cholecystitis and Cholelithiasis	PH2.3 Explain the rationale and demonstrate the emergency use of various sympathetic and parasympathetic drug agonists/antagonists like Noradrenaline/ Adrenaline/Dopamine/Dobutamine, Atropine) in case-based scenarios (SGT/CBL)	MI 9.2 Describe the etiopathogenesis and laboratory diagnosis of opportunistic infections(OI) along with factors predisposing to the development of OI by bacterial, viral, fungal and parasitic agents. (SGT)		MI 9.4 Describe the etiopathogenesis of infective causes of malignancy and explain the mechanisms used by oncogenic viruses in the development of virus-associated malignancies, along with their preventive measures. (SGT)	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH		LUNCH	
01.30 – 02.30 P.M.	PH2.3 Explain the rationale and demonstrate the emergency use of various sympathetic and parasympathetic drug agonists/antagonists like Noradrenaline/Adrenaline/Dopamine/Dobutamine, Atropine) in case-based scenarios (SGT/CBL)	MI 9.1.3 Explain etio-pathogenesis, vectors, clinical course, transmission, risk factors, laboratory diagnosis, and preventive & control strategies of different zoonotic infections caused by fungal & parasitic agents. (LGT)	PA24.6 Interpret liver function and viral hepatitis serology panel. Distinguish obstructive from non-obstructive jaundice based on clinical features and liver function tests	PH1.13 Identify and describe the management of drug interactions (SGT)		Revision Hepatobiliary System	
02.30 – 03.30 P.M.	PA24.7 Define and describe the etiology, types, pathogenesis, morphology and complications of Hepatocellular Carcinoma	PRACTICALS MICRO/PATH/PHARM				Revision Hepatobiliary System	
03.30 – 04.30 P.M.	FM 4.4 Describe and discuss identification of criminals, unknown persons, dead bodies from the remains-hairs, fibers, teeth, anthropometry	Communicate with the patient regarding opti (P/SGT) Microbiology: MI 1.10, 4.4 Stool microscopy- (Practical assessment)	action with pharmaceutical representative/media to get, imal use of a drug therapy using empathy and profession - Certifiable skill & MI 10.3 Personal protective equipment imicroscopic features of liver diseases and tumors tests		FM4.5 Dactylography, footprints, scars, tattoos, poroscopy and superimposition		

	29-06-2026	30-06-2026	01-07-2026	02-07-2026	03-07-2026	04-07-2026	05-07-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	PHARM AITO HYPERTENSION	
11.30 – 12.30 P.M.	SU 9.1 CHOOSE APPROPRIATE BIOCHEMICAL, MICROBIOLOGICAL, PATHOLOGICAL, I MAGING INVESTIGATIONS AND INTERPRET, THE INVESTIGATIVE DATA IN A SURGICAL PATIENT.	PA32.2 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications and metastases of bone tumors	PH 1.10 Describe changes in pharmacology of drugs in geriatric, pediatric and special situations such as Pregnancy, lactation, hepatic and renal disorders and adjust the drug treatment accordingly (SGT/PBL)	clinical course & laboratory diagnosis of bone & joint infections caused by bacterial,	PH IA 7.1-7.9 (Endocrine)	MI 5.3.2 Explain the etiopathogenesis, clinical course and the laboratory diagnosis of skin and soft tissue infections caused by fungal agents (superficial and subcutaneous mycoses) (LGT)	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	
	PH 3.9 Describe the drugs that are abused and cause addiction (dependence, addiction, stimulants, depressants, psychedelics, drugs used for criminal offences). Explain the process and steps for management of drug de addiction (SGT)	MI 5.1 Enumerate the microbial agents causing anaerobic infections. Describe the pathogenesis, clinical course and the laboratory diagnosis of anaerobic infections. (LGT)	PA32.2 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications and metastases of bone tumors	PA32.4 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications of Paget's disease of the bone	MI 5.3.3 Explain the etiopathogenesis, clinical course and the laboratory diagnosis of skin and soft tissue infections caused by viral and parasitic agents. (SGT)		
02.30 – 03.30 P.M.	PA32.1 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications of osteomyelitis	PRACTICALS MICRO/PATH/PHARM			PH IA Viva 7.1-7.9 (Endocrine)	PA32.5 Classify and describe the etiology, immunology, pathogenesis, manifestations, radiologic and laboratory features, diagnostic criteria and complications of rheumatoid arthritis	
	FM5.1 Define, describe and classify different types of mechanical injuries, abrasion, bruise, laceration, stab wound, incised wound, chop wound, defense wound, self-inflicted/fabricated wounds and their medico-legal aspects	pharmacotherapy; PH10.16 Demonstrate a recommend the line of management; PH10 drug dependence and OTC drugs Microbiology: MI 5.3, 9.3 Culture discussion		kely to produce dependence and about various aspects of drug use including (SGT case based discussion)	MI 5.3.1 Explain the etiopathogenesis, clinical course and the laboratory diagnosis of skin and soft tissue infections caused by bacterial agents. (LGT)	FM5.2 Define injury, assault & hurt. Describe Bharatiya Nyay Sanhita (BNS) pertaining to injuries	

	06-07-2026	07-07-2026	08-07-2026	09-07-2026	10-07-2026	11-07-2026	12-07-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
11.30 – 12.30 P.M.	causes and syndromic management of comon	PA32.3 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications and metastases of soft tissue tumors		MI 5.5 Describe the etiopathogenesis, clinical course, complications and laboratory diagnosis of mycobacterial infections involving skin & soft tissue with special emphasis on sample collection from/of skin (SDL)	PH IA 5.1,5.2 (RS), 6.1-6.5 (GIT) Miscellaneous		
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.	PHARM REVISION	MI 5.4 Differentiate between infective and non- infective lesions in the skin. Enlist microbes causing systemic disease with involvement of skin. (LGT)	PA33.1 Describe the risk factors pathogenesis, pathology and natural history of squamous cell carcinoma of the skin	PHARM REVISION	PA33.2 Describe the risk factors pathogenesis, pathology and natural history of basal cell carcinoma of the skin		
02.30 – 03.30 P.M.	PA32.6 Classify and describe the etiology, pathogenesis, manifestations, radiologic and laboratory features, diagnostic criteria and complications of Osteo arthritis and Gouty arthritis				PH IA Viva 5.1,5.2 (RS), 6.1-6.5 (GIT), Miscellaneous		
03.30 – 04.30 P.M.	FM5.3 Describe accidental, suicidal and homicidal injuries. Describe simple, grievous and dangerous injuries. Describe ante-mortem and post-mortem injuries	(Practical assessment)	logy PH6.3 Preparation of ORS gy: MI 9.3 Bacteriology, Virology, Mycology practical exercises				

	13-07-2026	14-07-2026	15-07-2026	16-07-2026	17-07-2026	18-07-2026	19-07-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	AITO - Pathology Thyroid Pathology	
11.30 – 12.30 P.M.	DIABETES - PATHOGENESIS & COMPLICATIONS GM11.1 - Define and classify diabetes GM11.2 - Describe and discuss the epidemiology and pathogenesis and risk factors and clinical evolution of type 1 diabetes GM11.3 - Describe and discuss the epidemiology and pathogenesis and risk factors economic impact and clinical evolution of type 2 diabetes GM11.4 - Describe and discuss the genetic background and the influence of the environment on diabetes GM11.5 - Describe and discuss the pathogenesis and temporal evolution of microvascular and macrovascular complications of diabetes GM11.16 - Discuss and describe the pharmacologic therapies for diabetes their indications, contraindications, adverse reactions and interactions GM11.7 - Outline a therapeutic approach to therapy of T2Diabetes based on presentation, severity and complications in a cost effective manner	iodine dependency of thyroid swellings	PHARM REVISION	MI 9.6 Describe the National Health Programs in the prevention of common infectious diseases and discuss the National reference centres for disease diagnosis and control (LGT)	PHARM REVISION	MICRO	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	
01.30 – 02.30 P.M.	PHARM REVISION	MI 9.5 Describe the concept of emerging & re-emerging with received in the concept of emerging and boratory and imaging features and course of their disease and strategies for emergence and re-emergence of their prevention and control. Describe outbreak investigations and bioterrorism (SDL) PA31.2 Describe the etiology, cause, iodine dependency, pathogenesis, manifestations, laboratory and imaging features and course of thyrotoxicosis and bioterrorism (SDL) Describe and discuss the pathogenesis and precipitating factors, recognition and management of diabetic emergencies GM11.14 - Recognise the presentation of hypoglycaemia and outline the principles on its therap GM11.6 - Discuss and describe the pharmacologic therapies for diabetes their indications, contraindications, adverse reactions and interactions GM11.22 - Enumerate the causes of hypoglycaemia and describe the counter		PA31.4 Classify and describe the epidemiology, etiology, pathogenesis, pathology, clinical laboratory features & complications of Thyroid tumors	OG 30.1 Etiopathogenesis, clinical features, differential diagnosis, investigations, managament, complications of PCOS OG 25.1 Causes of primary and secondary amenorrhea		
02.30 – 03.30 P.M.	PA33.3 Describe the distinguishing features between a news and melanoma. Describe the etiology, pathogenesis, risk factors morphology clinical features and metastases of melanoma				DIABETIC EMERGENCIES - DKA AND HONK - GM11.23-Describe the precipitating causes, pathophysiology, recognition, clinical features, diagnosis, stabilisation and management of diabetic ketoacidosis GM11.24 - Describe the precipitating causes, pathophysio-logy, recognition, clinical features, diagnosis, stabilisation and management of Hyperosmolar non ketotic state	PA31.8 Describe the etiology, pathogenesis, manifestations, laboratory, morphologic features, complications of adrenal insufficiency	
03.30 – 04.30 P.M.	FMS.4 Describe healing of injury and fracture of bones with its medico-legal importance	PRACTICALS MICRO/PATH/PHAR Pathology : HPE – BCC, Melanom Gross – Melanoma, SCC			Musculoskeletal system, Skin & soft tissue infections, Zoonotic infections & Miscellaneous (MI 5.1 to 5.5, 9.1 to 9.6) (Theory assessment)	FM5.5 Describe factors influencing infliction of injuries and healing, examination and certification of wounds and wound as a cause of death: Primary and Secondary	

	20-07-2026	21-07-2026	22-07-2026	23-07-2026	24-07-2026 25-07-2026			
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	26-07-2026 SUNDAY	
08.00 – 11.00 A.M.		CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CUNICAL POSTINGS	PHARM AITO-DIABETES MELLITUS		
11.30 – 12.30 P.M.	SU 9.2 BIOLOGICAL BASIS FOR EARLY DETECTION OF CANCER AND MULTICISCIPLINARY APPROACH IN MANAGEMENT OF CANCER.		PHARM REVISION	MICRO	PHARM REVISION MICRO			
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.				PA35.1 Describe the etiology, genetics, pathogenesis, pathology, presentation, sequelae and complications of retinoblastoma	PA31.5 Classify and describe the epidemiology, etiology, pathogenesis, pathology, clinical laboratory features, complications and progression of diabetes mellitus			
02.30 – 03.30 P.M.	PA31.9 Describe the etiology, pathogenesis, manifestations, laboratory, morphologic features, complications of Cushing's syndrome				PHARM REVISION	PA31.5 Classify and describe the epidemiology, etiology, pathogenesis, pathology, clinical laboratory features, complications and progression of diabetes mellitus		
03.30 - 04.30 P.M.	FM5.6 Describe and discuss different types of weapons including dangerous weapons and their examination	PRACTICALS MICRO/PATH/PHARM Pathology: Cytology – Hashimoto thyroiditis, colloid goitre HPE – Nodular colloid goitre, Hashimoto thyroiditis, PAP CA thyroid Gross - Hashimoto thyroiditis, colloid goitre Ospe Charts - Endocrine organs			OBESITY RISK FACTORS GM14.1 -Define and measure obesity as it relates to the Indian population GM14.2 -Describe and discuss the aetiology of obesity including modifiable and non-modifiable risk factors and secondary causes GM14.3 -Describe and discuss the impact of environmental factors including eating habits, food, work, environment and physical activity on the incidence of obesity GM14.5 - Describe and discuss the natural history of obesity and its complications	FM6.1 Describe different types of firearms including structure and components. Along with description of ammunition propellant charge and mechanism of firearms, different types of cartridges and bullets and various terminology in relation of firearm – caliber, range, choking		

	27-07-2026	28-07-2026	29-07-2026	30-07-2026	31-07-2026	01-08-2026	02-08-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	AETCOM/ AITO/IA	
	OG 33.4 Cancer Cervix screening - Pap smear, Virsual inspection with acetic acid (VIA), Virsual inspections of cervix with Logol's lodine (VILI).	Revision - General Pathology	PHARM REVISION	MICRO	PHARM REVISION	MICRO	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	
01.30 – 02.30 P.M.	PHARM REVISION	MICRO	Revision - Urine analysis Peripheral Smear and DLC, Hemoglobin estimation, Blood Grouping and typing Slides - HPC, Cytology, Hematology Gross specimens, Instruments	PHARM REVISION	Revision - OSPE charts, Clinical Interpretation Skills charts	MICRO/PATH/PHARM	
02.30 – 03.30 P.M.	OBESITY MANAGEMENT GM14.10 - Describe the indications and interpret the results of tests for secondary causes of obesity GM14.13 - Describe and enumerate the indications, pharmacology, and side effects of pharmacotherapy for obesity and describe and enumerate indications and side effects bariatric surgery GM14.14 - Describe and enumerate and educate patients, health care workers and the public on measures to prevent obesity and promote a healthy lifestyle				PHARM REVISION	РАТН	
	FM6.2 Describe and discuss wound ballistics-different types of firearm injuries, blast injuries and their interpretation, preservation and dispatch of trace evidences in cases of firearm and blast injuries, various tests related to confirmation of use of firearms	PRACTICALS MICRO/PATH/PI Pathology - Practicals Revisio		MICRO	FM		

	03-08-2026	04-08-2026	05-08-2026	06-08-2026	07-08-2026	08-08-2026	09-08-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS						
11.30 – 12.30 P.M.		РАТН	PHARM	MICRO	PHARM		
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.	PHARM	MICRO	РАТН	PHARM	РАТН		
02.30 – 03.30 P.M.	ратн				PHARM		
03.30 – 04.30 P.M.	FM		MICRO				

	10-08-2026	11-08-2026	12-08-2026	13-08-2026	14-08-2026	15-08-2026	16-08-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS		
11.30 – 12.30 P.M.	CLINICAL THEORY	РАТН	PHARM	MICRO	PHARM		
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH		
01.30 – 02.30 P.M.	PHARM	MICRO	ратн	PHARM	PATH		
02.30 – 03.30 P.M.	ратн				PHARM		
03.30 – 04.30 P.M.	FM		PRACTICALS MICRO/PATH/PHARM	MICRO			

	17-08-2026	18-08-2026	19-08-2026	20-08-2026	21-08-2026	22-08-2026	23-08-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	CLINICAL POSTINGS	AETCOM/ AITO/IA	
11.30 – 12.30 P.M.	CLINICAL THEORY	РАТН	PHARM	MICRO	PHARM	MICRO	
12.30 – 01.30 P.M.	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH	
01.30 – 02.30 P.M.	PHARM	MICRO	ратн	PHARM	РАТН	MICRO/PATH/PHARM	
02.30 – 03.30 P.M.	ратн				PHARM	PATH	
03.30 – 04.30 P.M.	FM		PRACTICALS MICRO/PATH/PHARM	MICRO	FM		

	24-08-2026	25-08-2026	26-08-2026	27-08-2026	28-08-2026	29-08-2026	30-08-2026	31-08-2026
TIME	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	SUNDAY	MONDAY
08.00 – 11.00 A.M.	CLINICAL POSTINGS			CLINICAL POSTINGS	CLINICAL POSTINGS	AETCOM/ AITO/IA		CLINICAL POSTINGS
11.30 – 12.30 P.M.	CLINICAL THEORY		PHARM	MICRO	PHARM	MICRO		CLINICAL THEORY
12.30 – 01.30 P.M.	LUNCH		LUNCH	LUNCH	LUNCH	LUNCH		LUNCH
01.30 – 02.30 P.M.	PHARM		ратн	PHARM	ратн	MICRO/PATH/PHARM		PHARM
02.30 – 03.30 P.M.	РАТН				PHARM	PATH		PATH
03.30 – 04.30 P.M.	FM		PRACTICALS MICRO/PATH/PHARM		MICRO	FM		FM